Code | Display | Comments |
---|
HIV.A.DE1 | First name | |
HIV.A.DE2 | Family name | |
HIV.A.DE3 | Visit date | |
HIV.A.DE4 | Referral | |
HIV.A.DE5 | Referred by | |
HIV.A.DE6 | Community | |
HIV.A.DE7 | Facility | |
HIV.A.DE8 | Unique identifier | |
HIV.A.DE9 | National ID | |
HIV.A.DE10 | National health ID | |
HIV.A.DE11 | National programme ID | |
HIV.A.DE12 | National health insurance ID | |
HIV.A.DE13 | Country of birth | |
HIV.A.DE14 | Date of birth | |
HIV.A.DE15 | Date of birth unknown | |
HIV.A.DE16 | Estimated age | |
HIV.A.DE17 | Age | |
HIV.A.DE18 | Gender | |
HIV.A.DE19 | Female | |
HIV.A.DE20 | Male | |
HIV.A.DE21 | Transgender male | |
HIV.A.DE22 | Transgender female | |
HIV.A.DE23 | Other | |
HIV.A.DE24 | Other (specify) | |
HIV.A.DE25 | Sex | |
HIV.A.DE26 | Female | |
HIV.A.DE27 | Male | |
HIV.A.DE28 | Other | |
HIV.A.DE29 | Address | |
HIV.A.DE30 | Marital Status | |
HIV.A.DE31 | Unmarried | |
HIV.A.DE32 | Never married | |
HIV.A.DE33 | Married | |
HIV.A.DE34 | Polygamous | |
HIV.A.DE35 | Divorced | |
HIV.A.DE36 | Widowed | |
HIV.A.DE37 | Unknown | |
HIV.A.DE38 | Domestic partner | |
HIV.A.DE39 | Annulled | |
HIV.A.DE40 | Legally separated | |
HIV.A.DE41 | Interlocutory | |
HIV.A.DE42 | Telephone number | |
HIV.A.DE43 | Administrative Area | |
HIV.A.DE44 | Communication consent | |
HIV.A.DE45 | Reminder messages | |
HIV.A.DE46 | Communication preference(s) | |
HIV.A.DE47 | Text message/SMS | |
HIV.A.DE48 | Voice call | |
HIV.A.DE49 | Client's email | |
HIV.A.DE50 | Alternate contact's name | |
HIV.A.DE51 | Alternate contact's phone number | |
HIV.A.DE52 | Alternate contact's address | |
HIV.A.DE53 | Alternate contact relationship | |
HIV.B.DE1 | Reason for visit | |
HIV.B.DE2 | First-time HIV test | |
HIV.B.DE3 | Retesting for HIV | |
HIV.B.DE4 | HIV testing services visit | |
HIV.B.DE5 | Referred through partner services | |
HIV.B.DE6 | Partner or contact of an index case | |
HIV.B.DE7 | Partner or contact of an HIV testing client (non-index case) | |
HIV.B.DE8 | Type of contact or partner for partner services | |
HIV.B.DE9 | Biological child | |
HIV.B.DE10 | Drug-injecting partner | |
HIV.B.DE11 | Sexual partner | |
HIV.B.DE12 | Social contact | |
HIV.B.DE13 | Contact with and (suspected) exposure to HIV | |
HIV.B.DE14 | Date/time of suspected exposure to HIV | |
HIV.B.DE15 | Testing entry point | |
HIV.B.DE16 | Community-level testing | |
HIV.B.DE17 | Facility-level testing | |
HIV.B.DE18 | Entry point for community-level testing | |
HIV.B.DE19 | Mobile testing (e.g. through vans or temporary testing facilities) | |
HIV.B.DE20 | Voluntary counselling and testing centres (not within a health facility setting) | |
HIV.B.DE21 | Other community-based testing | |
HIV.B.DE22 | Entry point for facility-level testing | |
HIV.B.DE23 | Provider-initiated tested in a clinic or emergency facility | |
HIV.B.DE24 | Antenatal care clinic | |
HIV.B.DE25 | Voluntary counselling and testing (within a health facility setting) | |
HIV.B.DE26 | Family planning clinic | |
HIV.B.DE27 | Other facility-level testing | |
HIV.B.DE28 | Tuberculosis (TB) clinic | |
HIV.B.DE29 | Currently pregnant | |
HIV.B.DE30 | Gestational age | |
HIV.B.DE31 | Expected date of delivery (EDD) | |
HIV.B.DE32 | Breastfeeding | |
HIV.B.DE33 | Partner HIV status (reported) | |
HIV.B.DE34 | HIV-positive | |
HIV.B.DE35 | HIV-negative | |
HIV.B.DE36 | Unknown | |
HIV.B.DE37 | Partner is from a key population | |
HIV.B.DE38 | Sex worker | |
HIV.B.DE39 | Men who have sex with men | |
HIV.B.DE40 | Trans and gender-diverse people | |
HIV.B.DE41 | People who inject drugs | |
HIV.B.DE42 | People living in prisons and other closed settings | |
HIV.B.DE43 | Has used an HIV self-test before (reported) | |
HIV.B.DE44 | HIV self-test result | |
HIV.B.DE45 | Reactive | |
HIV.B.DE46 | Non-reactive | |
HIV.B.DE47 | Invalid | |
HIV.B.DE48 | Date of HIV self-test | |
HIV.B.DE49 | Key population member | |
HIV.B.DE50 | Key population member type | |
HIV.B.DE51 | Sex worker | |
HIV.B.DE52 | Men who have sex with men | |
HIV.B.DE53 | Trans and gender-diverse people | |
HIV.B.DE54 | People who inject drugs | |
HIV.B.DE55 | People living in prisons and other closed settings | |
HIV.B.DE56 | Adolescent girl | |
HIV.B.DE57 | Young woman | |
HIV.B.DE58 | Orphan or vulnerable child | |
HIV.B.DE59 | Informed of HIV test result | |
HIV.B.DE60 | Date HIV test results returned | |
HIV.B.DE61 | HIV exposure type | |
HIV.B.DE62 | Occupational | |
HIV.B.DE63 | Non-occupational violent | |
HIV.B.DE64 | Non-occupational consensual sex | |
HIV.B.DE65 | Date informed of HIV-positive diagnosis | |
HIV.B.DE66 | HIV diagnosing facility | |
HIV.B.DE67 | Date of first positive test indicative of HIV diagnosis | |
HIV.B.DE68 | HIV serotype | |
HIV.B.DE69 | HIV-1 | |
HIV.B.DE70 | HIV-2 | |
HIV.B.DE71 | HIV diagnosis date | |
HIV.B.DE72 | ART start date | |
HIV.B.DE73 | Age at diagnosis | |
HIV.B.DE74 | Type of contact elicited | |
HIV.B.DE75 | Biological child | |
HIV.B.DE76 | Drug-injecting partner | |
HIV.B.DE77 | Sexual partner | |
HIV.B.DE78 | Social contact | |
HIV.B.DE79 | HIV test ordered | |
HIV.B.DE80 | HIV test conducted | |
HIV.B.DE81 | HIV test type | |
HIV.B.DE82 | Rapid diagnostic test for HIV | |
HIV.B.DE83 | Enzyme immunoassay for HIV | |
HIV.B.DE84 | Nucleic acid test for HIV | |
HIV.B.DE85 | Dual HIV/syphilis rapid diagnostic test | |
HIV.B.DE86 | HIV self-test | |
HIV.B.DE87 | Date HIV test sent | |
HIV.B.DE88 | Assay number in testing strategy | |
HIV.B.DE89 | Assay 0 | |
HIV.B.DE90 | Assay 1 | |
HIV.B.DE91 | Assay 2 | |
HIV.B.DE92 | Assay 3 | |
HIV.B.DE93 | Assay 1 repeated | |
HIV.B.DE94 | Test result of HIV assay 1 | |
HIV.B.DE95 | Reactive | |
HIV.B.DE96 | Non-reactive | |
HIV.B.DE97 | Invalid | |
HIV.B.DE98 | Test result of HIV assay 2 | |
HIV.B.DE99 | Reactive | |
HIV.B.DE100 | Non-reactive | |
HIV.B.DE101 | Invalid | |
HIV.B.DE102 | Test result of HIV assay 3 | |
HIV.B.DE103 | Reactive | |
HIV.B.DE104 | Non-reactive | |
HIV.B.DE105 | Invalid | |
HIV.B.DE106 | Test result of HIV assay 1 repeated | |
HIV.B.DE107 | Reactive | |
HIV.B.DE108 | Non-reactive | |
HIV.B.DE109 | Invalid | |
HIV.B.DE110 | HIV test date | |
HIV.B.DE111 | HIV test result | |
HIV.B.DE112 | HIV-positive | |
HIV.B.DE113 | HIV-negative | |
HIV.B.DE114 | HIV-inconclusive | |
HIV.B.DE115 | HIV status | |
HIV.B.DE116 | HIV-positive | |
HIV.B.DE117 | HIV-negative | |
HIV.B.DE118 | Unknown | |
HIV.B.DE119 | Date positive HIV test confirmed | |
HIV.B.DE120 | Site where positive HIV test confirmed | |
HIV.B.DE121 | Probable route of transmission | |
HIV.B.DE122 | Heterosexual sex | |
HIV.B.DE123 | Sex between men | |
HIV.B.DE124 | Unprotected intercourse during sex work | |
HIV.B.DE125 | Injecting drug use with unsterile equipment | |
HIV.B.DE126 | Nosocomial | |
HIV.B.DE127 | Vertical | |
HIV.B.DE128 | Other | |
HIV.B.DE129 | Partner HIV test conducted | |
HIV.B.DE130 | Partner HIV test ordered | |
HIV.B.DE131 | Partner HIV test date | |
HIV.B.DE132 | Partner HIV test result | |
HIV.B.DE133 | HIV-positive | |
HIV.B.DE134 | HIV-negative | |
HIV.B.DE135 | HIV-inconclusive | |
HIV.B.DE136 | Partner HIV status (confirmed) | |
HIV.B.DE137 | HIV-positive | |
HIV.B.DE138 | HIV-negative | |
HIV.B.DE139 | Unknown | |
HIV.B.DE140 | Partner on ART | |
HIV.B.DE141 | Partner virally suppressed on ART | |
HIV.B.DE142 | Counselling provided | |
HIV.B.DE143 | HIV-positive counselling conducted | |
HIV.B.DE144 | Hepatitis B positive counselling conducted | |
HIV.B.DE145 | Hepatitis C positive counselling conducted | |
HIV.B.DE146 | Syphilis counselling, treatment and further testing | |
HIV.B.DE147 | Linked to enrolment in care and ART initiation | |
HIV.B.DE148 | VMMC counselling provided | |
HIV.B.DE149 | Prevention services offered and referrals | |
HIV.B.DE150 | Offer male and female condoms and condom-compatible lubricants | |
HIV.B.DE151 | Offer pre-exposure prophylaxis (PrEP) for people at elevated risk for HIV acquisition | |
HIV.B.DE152 | Offer post-exposure prophylaxis (PEP) following suspected exposure | |
HIV.B.DE153 | Voluntary medical male circumcision (VMMC) | |
HIV.B.DE154 | Harm reduction for people who inject drugs | |
HIV.B.DE155 | Behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations | |
HIV.B.DE156 | HIV testing for partners and biological children | |
HIV.B.DE157 | HIV testing for partners and social contacts of people from key populations, where appropriate | |
HIV.B.DE158 | Sexual and reproductive health integrated services | |
HIV.B.DE159 | Contraception and family planning | |
HIV.B.DE160 | Check pregnancy status | |
HIV.B.DE161 | Prevention of mother-to-child transmission counselling | |
HIV.B.DE162 | Cervical cancer screening and treatment counselling | |
HIV.B.DE163 | Anal cancer screening (for men who have sex with men) | |
HIV.B.DE164 | STI testing and treatment services | |
HIV.B.DE165 | Offer other clinical services | |
HIV.B.DE166 | Assessment and provision of vaccinations | |
HIV.B.DE167 | Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment provided | |
HIV.B.DE168 | Co-trimoxazole chemoprophylaxis to prevent Pneumocystis carinii pneumonia provided | |
HIV.B.DE169 | Intensified TB case finding and linkage to TB treatment provided | |
HIV.B.DE170 | Provision of isoniazid preventive therapy if person does not have TB | |
HIV.B.DE171 | Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology | |
HIV.B.DE172 | Other support services | |
HIV.B.DE173 | Mental health services | |
HIV.B.DE174 | Psychosocial counselling, support and treatment adherence counselling | |
HIV.B.DE175 | Support for disclosure and partner services | |
HIV.B.DE176 | Legal and social services | |
HIV.B.DE177 | Services for responding to violence against women | |
HIV.B.DE178 | Clinical enquiry for intimate partner violence (IPV) done | |
HIV.B.DE179 | Intimate partner violence enquiry results | |
HIV.B.DE180 | Client received treatment and/or counselling as needed | |
HIV.B.DE181 | Client was referred | |
HIV.B.DE182 | No action necessary | |
HIV.B.DE183 | Other IPV result | |
HIV.B.DE184 | Other IPV result (specify) | |
HIV.B.DE185 | Offered voluntary partner services | |
HIV.B.DE186 | Count of contacts or partners given for social network-based/partner services | |
HIV.B.DE187 | Offered social network-based/partner services | |
HIV.B.DE188 | Accepted social network-based/partner services | |
HIV.B.DE189 | Contact first name to offer social network-based/partner services | |
HIV.B.DE190 | Contact last name to offer social network-based/partner services | |
HIV.B.DE191 | Type of follow-up appointment | |
HIV.B.DE192 | Retesting for HIV | |
HIV.B.DE193 | Other | |
HIV.B.DE194 | Other reason for the follow-up appointment (specify) | |
HIV.B.DE195 | Date/time of follow-up appointment | |
HIV.B.DE196 | Recommended follow-up date | |
HIV.B.DE197 | VMMC procedure | |
HIV.B.DE198 | VMMC procedure date | |
HIV.B.DE199 | Adverse event reported from a VMMC | |
HIV.B.DE200 | Serious adverse event | |
HIV.B.DE201 | Adverse event severity | |
HIV.B.DE202 | Moderate | |
HIV.B.DE203 | Severe | |
HIV.B.DE204 | Timing of adverse event | |
HIV.B.DE205 | Intraoperative | |
HIV.B.DE206 | Postoperative | |
HIV.B.DE207 | Type of adverse VMMC event | |
HIV.B.DE208 | Abnormal pain | |
HIV.B.DE209 | Anaesthesia-related effects | |
HIV.B.DE210 | Bleeding | |
HIV.B.DE211 | Damage to the penis | |
HIV.B.DE212 | Difficulty urinating | |
HIV.B.DE213 | Excessive bleeding | |
HIV.B.DE214 | Excessive skin removal | |
HIV.B.DE215 | Excessive swelling | |
HIV.B.DE216 | Haematoma | |
HIV.B.DE217 | Infection | |
HIV.B.DE218 | Injury to glans | |
HIV.B.DE219 | Scar or disfigurement | |
HIV.B.DE220 | Sharps injury to personnel | |
HIV.B.DE221 | Wound disruption | |
HIV.B.DE222 | Other | |
HIV.B.DE223 | Other (specify) | |
HIV.B.DE224 | HIV retest prior to starting ART conducted | |
HIV.B.DE225 | At elevated risk for HIV acquisition | |
HIV.B.DE226 | Syndrome/STI diagnosed | |
HIV.B.DE227 | Urethral discharge syndrome | |
HIV.B.DE228 | Vaginal discharge syndrome | |
HIV.B.DE229 | Lower Abdominal pain | |
HIV.B.DE230 | Genital ulcer disease syndrome | |
HIV.B.DE231 | Anorectal discharge | |
HIV.B.DE232 | Sent for testing | |
HIV.B.DE233 | Other | |
HIV.B.DE234 | Other (specify) | |
HIV.B.DE235 | Any STI syndrome diagnosed | |
HIV.B.DE236 | Date of STI test | |
HIV.B.DE237 | STI tested for | |
HIV.B.DE238 | Neisseria gonorrhoeae | |
HIV.B.DE239 | Chlamydia trachomatis | |
HIV.B.DE240 | Trichomonas vaginalis | |
HIV.B.DE241 | Syphilis (Treponema pallidum) | |
HIV.B.DE242 | Herpes simplex virus (HSV1, HSV2) | |
HIV.B.DE243 | Mycoplasma genitalium | |
HIV.B.DE244 | Mpox | |
HIV.B.DE245 | Hepatitis B | |
HIV.B.DE246 | Hepatitis C | |
HIV.B.DE247 | Other | |
HIV.B.DE248 | Other (specify) | |
HIV.B.DE249 | Syphilis test date | |
HIV.B.DE250 | Syphilis test result | |
HIV.B.DE251 | Positive | |
HIV.B.DE252 | Negative | |
HIV.B.DE253 | Inconclusive | |
HIV.B.DE254 | Syphilis treatment start date | |
HIV.B.DE255 | Gonorrhoea test date | |
HIV.B.DE256 | Gonorrhoea test result | |
HIV.B.DE257 | Positive | |
HIV.B.DE258 | Negative | |
HIV.B.DE259 | Inconclusive | |
HIV.B.DE260 | Gonorrhoea treatment start date | |
HIV.B.DE261 | Type of specimen | |
HIV.B.DE262 | Blood | |
HIV.B.DE263 | Urine | |
HIV.B.DE264 | Cervical or vaginal swab | |
HIV.B.DE265 | Urethral or penile swab | |
HIV.B.DE266 | Rectal swab | |
HIV.B.DE267 | Other | |
HIV.B.DE268 | Other type of specimen (specify) | |
HIV.B.DE269 | Syphilis test type | |
HIV.B.DE270 | Treponemal | |
HIV.B.DE271 | Non-treponemal | |
HIV.B.DE272 | POC Test | |
HIV.B.DE273 | NAAT | |
HIV.B.DE274 | Other | |
HIV.B.DE275 | Other syphilis test type (specify) | |
HIV.B.DE276 | Neisseria gonorrhoeae test type | |
HIV.B.DE277 | NAAT | |
HIV.B.DE278 | POC Test | |
HIV.B.DE279 | Culture | |
HIV.B.DE280 | Microscopy | |
HIV.B.DE281 | Other | |
HIV.B.DE282 | Other (specify) | |
HIV.B.DE283 | POC Test for Neisseria gonorrhoeae (specify) | |
HIV.B.DE284 | Chlamydia trachomatis test type | |
HIV.B.DE285 | NAAT | |
HIV.B.DE286 | POC Test | |
HIV.B.DE287 | Culture | |
HIV.B.DE288 | ELISA | |
HIV.B.DE289 | Microscopy | |
HIV.B.DE290 | Other | |
HIV.B.DE291 | Other test for Chlamydia (specify) | |
HIV.B.DE292 | POC Test type for Chlamydia test (specify) | |
HIV.B.DE293 | Trichomonas vaginalis test type | |
HIV.B.DE294 | NAAT | |
HIV.B.DE295 | POC Test | |
HIV.B.DE296 | Culture | |
HIV.B.DE297 | Microscopy | |
HIV.B.DE298 | Other | |
HIV.B.DE299 | Other (specify) | |
HIV.B.DE300 | POC Test type for Trichomonas vaginalis test (specify) | |
HIV.B.DE301 | Herpes simplex virus (HSV) test type | |
HIV.B.DE302 | NAAT | |
HIV.B.DE303 | Antibody test | |
HIV.B.DE304 | Other | |
HIV.B.DE305 | Other (specify) | |
HIV.B.DE306 | Mycoplasma genitalium test type | |
HIV.B.DE307 | NAAT | |
HIV.B.DE308 | Microscopy | |
HIV.B.DE309 | Other | |
HIV.B.DE310 | Other (specify) | |
HIV.B.DE311 | Test type for other STI tested for (specify) | |
HIV.B.DE312 | STI test result | |
HIV.B.DE313 | Positive | |
HIV.B.DE314 | Negative | |
HIV.B.DE315 | Inconclusive | |
HIV.B.DE316 | Date of STI confirmatory test | |
HIV.B.DE317 | Confirmatory syphilis test type | |
HIV.B.DE318 | Treponemal | |
HIV.B.DE319 | Non-treponemal | |
HIV.B.DE320 | POC Test | |
HIV.B.DE321 | NAAT | |
HIV.B.DE322 | Other | |
HIV.B.DE323 | Other (specify) | |
HIV.B.DE324 | Confirmatory test type for other STI (specify) | |
HIV.B.DE325 | Confirmatory STI test result | |
HIV.B.DE326 | Positive | |
HIV.B.DE327 | Negative | |
HIV.B.DE328 | Inconclusive | |
HIV.B.DE329 | Date STI treatment prescribed | |
HIV.B.DE330 | Date STI treatment dispensed | |
HIV.B.DE331 | STI treatment dispensed (specify) | |
HIV.C.DE1 | Reason for PrEP visit | |
HIV.C.DE2 | First time counselling on PrEP | |
HIV.C.DE3 | Follow-up appointment for PrEP or PEP | |
HIV.C.DE4 | Restarting PrEP | |
HIV.C.DE5 | Counselling on PEP | |
HIV.C.DE6 | Unscheduled visit for side effects | |
HIV.C.DE7 | 3-month PrEP visit | |
HIV.C.DE8 | Contact with and (suspected) exposure to HIV | |
HIV.C.DE9 | Date/time of suspected exposure to HIV | |
HIV.C.DE10 | Currently on PrEP | |
HIV.C.DE11 | PrEP dosing type | |
HIV.C.DE12 | Daily oral PrEP | |
HIV.C.DE13 | Event-driven PrEP (2+1+1) | |
HIV.C.DE14 | Other PrEP dosing type | |
HIV.C.DE15 | Other PrEP dosing type (specify) | |
HIV.C.DE16 | Used event-driven PrEP for at risk exposures over the past 3 months | |
HIV.C.DE17 | Current PrEP regimen | |
HIV.C.DE18 | TDF + FTC | |
HIV.C.DE19 | TDF | |
HIV.C.DE20 | TDF + 3TC | |
HIV.C.DE21 | Other TDF-based regimen | |
HIV.C.DE22 | Dapivirine vaginal ring (DVR) | |
HIV.C.DE23 | CAB-LA | |
HIV.C.DE24 | Experience with PrEP | |
HIV.C.DE25 | First-time user | |
HIV.C.DE26 | Continuing user | |
HIV.C.DE27 | Restarting following a period of not taking PrEP | |
HIV.C.DE28 | PrEP start date | |
HIV.C.DE29 | Stopped PrEP | |
HIV.C.DE30 | Date PrEP stopped | |
HIV.C.DE31 | PEP history | |
HIV.C.DE32 | First-time user | |
HIV.C.DE33 | Repeat user | |
HIV.C.DE34 | Date(s) of past PEP use | |
HIV.C.DE35 | Date client completes PEP course | |
HIV.C.DE36 | Signs of substantial risk of HIV infection | |
HIV.C.DE37 | No condom use during sex with more than one partner in the past 6 months | |
HIV.C.DE38 | STI in the past 6 months | |
HIV.C.DE39 | A sexual partner in the past 6 months had one or more HIV risk factors | |
HIV.C.DE40 | PrEP requested by client | |
HIV.C.DE41 | Pregnancy intention in serodiscordant partnerships | |
HIV.C.DE42 | Yes, I want to become pregnant | |
HIV.C.DE43 | I'm OK either way | |
HIV.C.DE44 | No, I don't want to become pregnant | |
HIV.C.DE45 | Unsure | |
HIV.C.DE46 | Acute HIV infection symptoms | |
HIV.C.DE47 | Fever | |
HIV.C.DE48 | Sore throat | |
HIV.C.DE49 | Aches | |
HIV.C.DE50 | Pains | |
HIV.C.DE51 | Swollen glands | |
HIV.C.DE52 | Mouth sores | |
HIV.C.DE53 | Headaches | |
HIV.C.DE54 | Rash | |
HIV.C.DE55 | Sex partner's HIV treatment status | |
HIV.C.DE56 | Not on ART | |
HIV.C.DE57 | On ART less than 6 months | |
HIV.C.DE58 | Partner has suspected low adherence to ART | |
HIV.C.DE59 | Partner is not virally suppressed | |
HIV.C.DE60 | Partner is virally suppressed and has been on ART for 6 months or more | |
HIV.C.DE61 | Suitable for PrEP | |
HIV.C.DE62 | Offered PrEP | |
HIV.C.DE63 | Screenings and diagnostics for PrEP users | |
HIV.C.DE64 | Serum creatinine test | |
HIV.C.DE65 | Hepatitis B test | |
HIV.C.DE66 | Hepatitis C test | |
HIV.C.DE67 | Syphilis test | |
HIV.C.DE68 | Other screening for STIs | |
HIV.C.DE69 | Pregnancy testing | |
HIV.C.DE70 | Review vaccination history | |
HIV.C.DE71 | Serum creatinine test date | |
HIV.C.DE72 | Serum creatinine test result | |
HIV.C.DE73 | Date medications dispensed | |
HIV.C.DE74 | Date medications prescribed | |
HIV.C.DE75 | Medications prescribed | |
HIV.C.DE76 | PrEP for HIV prevention | |
HIV.C.DE77 | PEP for HIV prevention | |
HIV.C.DE78 | Other | |
HIV.C.DE79 | Other (specify) | |
HIV.C.DE80 | PrEP product prescribed | |
HIV.C.DE81 | Oral PrEP | |
HIV.C.DE82 | Dapivirine vaginal ring (DVR) | |
HIV.C.DE83 | CAB-LA | |
HIV.C.DE84 | Other | |
HIV.C.DE85 | Other (specify) | |
HIV.C.DE86 | Date PrEP prescribed | |
HIV.C.DE87 | Date PrEP dispensed | |
HIV.C.DE88 | Volume of PrEP product prescribed/dispensed | |
HIV.C.DE89 | Date PEP prescribed | |
HIV.C.DE90 | Date PEP course completion | |
HIV.C.DE91 | Preferred PEP backbone regimen | |
HIV.C.DE92 | TDF + 3TC | |
HIV.C.DE93 | TDF + FTC | |
HIV.C.DE94 | AZT + 3TC | |
HIV.C.DE95 | Alternative PEP backbone regimen | |
HIV.C.DE96 | ABC + 3TC | |
HIV.C.DE97 | TDF + 3TC | |
HIV.C.DE98 | TDF + FTC | |
HIV.C.DE99 | Preferred third PEP drug | |
HIV.C.DE100 | DTG | |
HIV.C.DE101 | Alternative third PEP drug | |
HIV.C.DE102 | ATV/r | |
HIV.C.DE103 | DRV/r | |
HIV.C.DE104 | LPV/r | |
HIV.C.DE105 | RAL | |
HIV.C.DE106 | Estimated creatinine clearance | |
HIV.C.DE107 | Sex factor for estimating creatinine clearance | |
HIV.C.DE108 | Male | |
HIV.C.DE109 | Female | |
HIV.C.DE110 | Estimated creatinine clearance (Cockcroft–Gault equation) | |
HIV.C.DE111 | Date of sample collection | |
HIV.C.DE112 | Contraindications to PrEP usage | |
HIV.C.DE113 | Tenofovir disoproxil fumarate (TDF) allergy or contraindication | |
HIV.C.DE114 | HIV-positive | |
HIV.C.DE115 | Low estimated creatinine clearance | |
HIV.C.DE116 | Acute HIV infection symptoms | |
HIV.C.DE117 | Probable recent exposure to HIV | |
HIV.C.DE118 | Other allergy or contraindication to a medicine in the PrEP regimen | |
HIV.C.DE119 | Other allergy or contraindication to a medicine in the PrEP regimen (specify) | |
HIV.C.DE120 | Prescribed PrEP at initial visit | |
HIV.C.DE121 | Number of days prescribed | |
HIV.C.DE122 | PrEP regimen prescribed | |
HIV.C.DE123 | Adherence counselling provided | |
HIV.C.DE124 | Date/time of follow-up appointment | |
HIV.C.DE125 | Type of follow-up appointment | |
HIV.C.DE126 | Retesting for HIV | |
HIV.C.DE127 | Follow-up appointment for PrEP | |
HIV.C.DE128 | Other | |
HIV.C.DE129 | Other (specify) | |
HIV.C.DE130 | Linked to enrolment in care and ART initiation | |
HIV.C.DE131 | Prevention services offered and referrals | |
HIV.C.DE132 | Male and female condoms and condom-compatible lubricants offered | |
HIV.C.DE133 | Voluntary medical male circumcision (VMMC) referral | |
HIV.C.DE134 | Harm reduction for people who inject drugs | |
HIV.C.DE135 | Behavioural interventions to support risk reduction | |
HIV.C.DE136 | Date provided condoms | |
HIV.C.DE137 | Condoms distributed | |
HIV.C.DE138 | Condom type | |
HIV.C.DE139 | Male condom | |
HIV.C.DE140 | Female condom | |
HIV.C.DE141 | HIV self-test kits accepted | |
HIV.C.DE142 | Number of HIV self-test kits distributed | |
HIV.C.DE143 | HIV self-test distributed for use by | |
HIV.C.DE144 | Self | |
HIV.C.DE145 | Family member | |
HIV.C.DE146 | Drug-injecting partner | |
HIV.C.DE147 | Sexual partner | |
HIV.C.DE148 | Social contact | |
HIV.C.DE149 | Sexual and reproductive health integrated services | |
HIV.C.DE150 | Contraception and family planning | |
HIV.C.DE151 | Check pregnancy status | |
HIV.C.DE152 | Prevent mother-to-child transmission | |
HIV.C.DE153 | Cervical cancer screening and treatment | |
HIV.C.DE154 | Anal cancer screening (for men who have sex with men) | |
HIV.C.DE155 | STI testing and treatment | |
HIV.C.DE156 | HIV testing for partners and biological children | |
HIV.C.DE157 | Offer other clinical services | |
HIV.C.DE158 | Assessment and provision of vaccinations | |
HIV.C.DE159 | Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing and treatment | |
HIV.C.DE160 | Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia | |
HIV.C.DE161 | Intensified TB case finding and linkage to TB treatment | |
HIV.C.DE162 | Provision of isoniazid preventive therapy if person does not have TB | |
HIV.C.DE163 | Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology | |
HIV.C.DE164 | Other support services | |
HIV.C.DE165 | Mental health services | |
HIV.C.DE166 | Psychosocial counselling, support and treatment adherence counselling | |
HIV.C.DE167 | Support for disclosure and partner services | |
HIV.C.DE168 | Legal and social services | |
HIV.C.DE169 | Services for responding to violence against women | |
HIV.D.DE1 | Reason for visit | |
HIV.D.DE2 | First clinical visit | |
HIV.D.DE3 | Clinical visit | |
HIV.D.DE4 | ART initiation | |
HIV.D.DE5 | ART drug pick up | |
HIV.D.DE6 | Issues and concerns | |
HIV.D.DE7 | Post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer | |
HIV.D.DE8 | Scheduled visit | |
HIV.D.DE9 | Body temperature | |
HIV.D.DE10 | Respiratory rate | |
HIV.D.DE11 | Heart rate | |
HIV.D.DE12 | Body height | |
HIV.D.DE13 | Body weight | |
HIV.D.DE14 | Systolic blood pressure | |
HIV.D.DE15 | Diastolic blood pressure | |
HIV.D.DE16 | Blood pressure cannot be taken | |
HIV.D.DE17 | Signs of serious illness | |
HIV.D.DE18 | Fever of 39 C or greater | |
HIV.D.DE19 | Tachycardia | |
HIV.D.DE20 | Tachypnea | |
HIV.D.DE21 | Unable to walk unaided | |
HIV.D.DE22 | Lethargy | |
HIV.D.DE23 | Unconsciousness | |
HIV.D.DE24 | Convulsions | |
HIV.D.DE25 | Unable to drink | |
HIV.D.DE26 | Unable to breastfeed | |
HIV.D.DE27 | Repeated vomiting | |
HIV.D.DE28 | Headache | |
HIV.D.DE29 | Other sign of serious illness | |
HIV.D.DE30 | Other sign of serious illness (specify) | |
HIV.D.DE31 | Currently pregnant | |
HIV.D.DE32 | Breastfeeding | |
HIV.D.DE33 | Number of pregnancies (gravida) | |
HIV.D.DE34 | Number of miscarriages and/or abortions | |
HIV.D.DE35 | Number of live births | |
HIV.D.DE36 | Parity | |
HIV.D.DE37 | Serodiscordant partner | |
HIV.D.DE38 | On ART | |
HIV.D.DE39 | ART start date | |
HIV.D.DE40 | Stopped ART | |
HIV.D.DE41 | Date ART stopped | |
HIV.D.DE42 | Established on ART | |
HIV.D.DE43 | ART start type | |
HIV.D.DE44 | First-time user of ART | |
HIV.D.DE45 | Restarting ART | |
HIV.D.DE46 | Date of initiation on ART | |
HIV.D.DE47 | Time on ART | |
HIV.D.DE48 | Date(s) ART restarted | |
HIV.D.DE49 | ART cohort | |
HIV.D.DE50 | Transfer in for HIV care | |
HIV.D.DE51 | Date of transfer in | |
HIV.D.DE52 | Facility transferred from | |
HIV.D.DE53 | Date enrolled in HIV care | |
HIV.D.DE54 | Age at enrolment | |
HIV.D.DE55 | Facility where client first enrolled in HIV care | |
HIV.D.DE56 | Antiretroviral (ARV) drugs received prior to enrolment | |
HIV.D.DE57 | No prior ARVs | |
HIV.D.DE58 | Received ARVs prior without records/documentation | |
HIV.D.DE59 | Received ARVs during pregnancy or breastfeeding | |
HIV.D.DE60 | Received ARVs for PEP or PrEP | |
HIV.D.DE61 | ARV prophylaxis for an HIV-exposed infant | |
HIV.D.DE62 | Date ARV drugs received prior to enrolment | |
HIV.D.DE63 | Location ARV drugs received prior to enrolment | |
HIV.D.DE64 | ARV drug regimen received prior to enrolment | |
HIV.D.DE65 | Existing chronic health conditions | |
HIV.D.DE66 | No chronic or past health conditions | |
HIV.D.DE67 | Don't know | |
HIV.D.DE68 | Diabetes other or unspecified | |
HIV.D.DE69 | Diabetes pre-existing type 1 | |
HIV.D.DE70 | Diabetes pre-existing type 2 | |
HIV.D.DE71 | Hypertension | |
HIV.D.DE72 | Other | |
HIV.D.DE73 | Other (specify) | |
HIV.D.DE74 | Original first-line ART regimen | |
HIV.D.DE75 | Current ART regimen | |
HIV.D.DE76 | Current ART regimen start date | |
HIV.D.DE77 | Preferred first-line ART regimen | |
HIV.D.DE78 | Alternative first-line ART regimen | |
HIV.D.DE79 | First-line ART regimen under special circumstances | |
HIV.D.DE80 | Preferred second-line ART regimen | |
HIV.D.DE81 | Alternative second-line ART regimen | |
HIV.D.DE82 | Optimal regimen for transition | |
HIV.D.DE83 | Current ART regimen (first-, second-, or third-line) | |
HIV.D.DE84 | First-line ART regimen for adults and adolescents | |
HIV.D.DE85 | First-line ART regimen for children | |
HIV.D.DE86 | First-line ART regimen for neonates | |
HIV.D.DE87 | Second-line ART regimen for adults and adolescents | |
HIV.D.DE88 | Second-line ART regimen for children | |
HIV.D.DE89 | Third-line ART regimen | |
HIV.D.DE90 | ART regimen | |
HIV.D.DE91 | ABC + 3TC + ATV/r | |
HIV.D.DE92 | ABC + 3TC + DTG | |
HIV.D.DE93 | ABC + 3TC + EFV | |
HIV.D.DE94 | ABC + 3TC + LPV/r | |
HIV.D.DE95 | ABC + 3TC + NVP | |
HIV.D.DE96 | ABC + 3TC + RAL | |
HIV.D.DE97 | AZT + 3TC + ATV/r | |
HIV.D.DE98 | AZT + 3TC + DRV/r | |
HIV.D.DE99 | AZT + 3TC + DTG | |
HIV.D.DE100 | AZT + 3TC + EFV | |
HIV.D.DE101 | AZT + 3TC + EFV 600 mg | |
HIV.D.DE102 | AZT + 3TC + LPV/r | |
HIV.D.DE103 | AZT + 3TC + NVP | |
HIV.D.DE104 | AZT + 3TC + RAL | |
HIV.D.DE105 | TAF + 3TC + DTG | |
HIV.D.DE106 | TAF + FTC + DTG | |
HIV.D.DE107 | TDF + 3TC + ATV/r | |
HIV.D.DE108 | TDF + 3TC + DRV/r | |
HIV.D.DE109 | TDF + 3TC + DTG | |
HIV.D.DE110 | TDF + 3TC + EFV | |
HIV.D.DE111 | TDF + 3TC + EFV 400 mg | |
HIV.D.DE112 | TDF + 3TC + EFV 600 mg | |
HIV.D.DE113 | TDF + 3TC + LPV/r | |
HIV.D.DE114 | TDF + 3TC + NVP | |
HIV.D.DE115 | TDF + 3TC + PI/r | |
HIV.D.DE116 | TDF + 3TC + RAL | |
HIV.D.DE117 | TDF + FTC + ATV/r | |
HIV.D.DE118 | TDF + FTC + DRV/r | |
HIV.D.DE119 | TDF + FTC + DTG | |
HIV.D.DE120 | TDF + FTC + EFV | |
HIV.D.DE121 | TDF + FTC + EFV 600 mg | |
HIV.D.DE122 | TDF + FTC + LPV/r | |
HIV.D.DE123 | TDF + FTC + NVP | |
HIV.D.DE124 | TDF + FTC + PI/r | |
HIV.D.DE125 | TDF + FTC + RAL | |
HIV.D.DE126 | Other | |
HIV.D.DE127 | Other (specify) | |
HIV.D.DE128 | ART regimen composition | |
HIV.D.DE129 | ABC | |
HIV.D.DE130 | FTC | |
HIV.D.DE131 | 3TC | |
HIV.D.DE132 | AZT | |
HIV.D.DE133 | DDI | |
HIV.D.DE134 | D4T | |
HIV.D.DE135 | TDF | |
HIV.D.DE136 | EFV | |
HIV.D.DE137 | ETV | |
HIV.D.DE138 | NVP | |
HIV.D.DE139 | RIL | |
HIV.D.DE140 | ATV/r | |
HIV.D.DE141 | LPV/r | |
HIV.D.DE142 | DRV/r | |
HIV.D.DE143 | RTV | |
HIV.D.DE144 | DTG | |
HIV.D.DE145 | RAL | |
HIV.D.DE146 | ART regimen drug class | |
HIV.D.DE147 | NRTI | |
HIV.D.DE148 | NtRTI | |
HIV.D.DE149 | NNRTI | |
HIV.D.DE150 | PI | |
HIV.D.DE151 | INSTI | |
HIV.D.DE152 | Prevention services offered and referrals | |
HIV.D.DE153 | Offer male and female condoms and condom-compatible lubricants | |
HIV.D.DE154 | Harm reduction for people who inject drugs | |
HIV.D.DE155 | Behavioural interventions to support risk reduction | |
HIV.D.DE156 | Sexual and reproductive health integrated services | |
HIV.D.DE157 | Contraception and family planning | |
HIV.D.DE158 | Check pregnancy status | |
HIV.D.DE159 | Prevention of mother-to-child transmission | |
HIV.D.DE160 | STI testing and treatment | |
HIV.D.DE161 | HBsAg test date | |
HIV.D.DE162 | HBsAg test result | |
HIV.D.DE163 | Positive | |
HIV.D.DE164 | Negative | |
HIV.D.DE165 | Indeterminate | |
HIV.D.DE166 | Date HBV test result returned to client | |
HIV.D.DE167 | HBV treatment (TDF) start date | |
HIV.D.DE168 | HBV treatment regimen prescribed | |
HIV.D.DE169 | HCV test date | |
HIV.D.DE170 | HCV test result | |
HIV.D.DE171 | Positive | |
HIV.D.DE172 | Negative | |
HIV.D.DE173 | Indeterminate | |
HIV.D.DE174 | Date HCV test result returned to client | |
HIV.D.DE175 | HCV treatment start date | |
HIV.D.DE176 | HCV treatment completion date | |
HIV.D.DE177 | HCV treatment regimen prescribed | |
HIV.D.DE178 | HCV viral load test date | |
HIV.D.DE179 | HCV viral load test result | |
HIV.D.DE180 | Detected | |
HIV.D.DE181 | Not detected | |
HIV.D.DE182 | HCV medicine type | |
HIV.D.DE183 | Interferon | |
HIV.D.DE184 | Direct acting antivirals | |
HIV.D.DE185 | Currently on TDF-based ART | |
HIV.D.DE186 | HIV clinical stage | |
HIV.D.DE187 | WHO HIV clinical stage 1 | |
HIV.D.DE188 | WHO HIV clinical stage 2 | |
HIV.D.DE189 | WHO HIV clinical stage 3 | |
HIV.D.DE190 | WHO HIV clinical stage 4 | |
HIV.D.DE191 | Number of missed doses | |
HIV.D.DE192 | Received viral load test result | |
HIV.D.DE193 | Date viral load test results received by client | |
HIV.D.DE194 | Date of viral load sample collection | |
HIV.D.DE195 | Date of scheduled review of viral load test results | |
HIV.D.DE196 | Date of ART interruption | |
HIV.D.DE197 | Reason(s) for adherence problem | |
HIV.D.DE198 | Forgot | |
HIV.D.DE199 | Toxicity/side effects | |
HIV.D.DE200 | Busy | |
HIV.D.DE201 | Change of routine | |
HIV.D.DE202 | Travel cost | |
HIV.D.DE203 | Distance to clinic | |
HIV.D.DE204 | Client lost/ran out of pills | |
HIV.D.DE205 | Stock-out | |
HIV.D.DE206 | Too ill | |
HIV.D.DE207 | Pill burden | |
HIV.D.DE208 | Felt well | |
HIV.D.DE209 | Depression | |
HIV.D.DE210 | Alcohol use | |
HIV.D.DE211 | Substance use | |
HIV.D.DE212 | Stigma/disclosure concerns | |
HIV.D.DE213 | Lack of food | |
HIV.D.DE214 | Poor palatability | |
HIV.D.DE215 | Other reason for nonadherence | |
HIV.D.DE216 | Other reason for nonadherence (specify) | |
HIV.D.DE217 | Reason ART stopped | |
HIV.D.DE218 | Toxicity/side effects | |
HIV.D.DE219 | Severe illness, hospitalization | |
HIV.D.DE220 | Drugs out of stock | |
HIV.D.DE221 | Client lacks finances | |
HIV.D.DE222 | Excluded HIV infection in infant | |
HIV.D.DE223 | Other reason for stopping ART | |
HIV.D.DE224 | Other reason for stopping ART (specify) | |
HIV.D.DE225 | Treatment failure | |
HIV.D.DE226 | Clinical failure | |
HIV.D.DE227 | Immunological failure | |
HIV.D.DE228 | Virological failure | |
HIV.D.DE229 | General care activities recommended | |
HIV.D.DE230 | Determine WHO clinical stage | |
HIV.D.DE231 | Determine if advanced disease | |
HIV.D.DE232 | Prepare for ART | |
HIV.D.DE233 | Prepare, assess and support adherence | |
HIV.D.DE234 | Manage current medications | |
HIV.D.DE235 | Check pregnancy status | |
HIV.D.DE236 | Provide family planning and contraception | |
HIV.D.DE237 | Support disclosure and partner notification | |
HIV.D.DE238 | Counsel on risk reduction and prevention | |
HIV.D.DE239 | Assess, prevent and manage noncommunicable diseases | |
HIV.D.DE240 | Screen for and manage mental health problems | |
HIV.D.DE241 | Screen for and manage and substance use issues | |
HIV.D.DE242 | Provide psychosocial counselling and support | |
HIV.D.DE243 | Manage pain and symptoms | |
HIV.D.DE244 | Conduct a nutritional assessment and counsel on nutrition | |
HIV.D.DE245 | Conduct a growth and development assessment | |
HIV.D.DE246 | Provide support on infant and child feeding | |
HIV.D.DE247 | Preventing and treating coinfections | |
HIV.D.DE248 | Provide co-trimoxazole preventive therapy (CPT) | |
HIV.D.DE249 | Intensified TB case finding and linkage to TB treatment | |
HIV.D.DE250 | Provide isoniazid preventive therapy | |
HIV.D.DE251 | Screen for cryptococcal infection and fungal prophylaxis | |
HIV.D.DE252 | Screen for hepatitis B | |
HIV.D.DE253 | Screen for hepatitis C | |
HIV.D.DE254 | Prevent malaria | |
HIV.D.DE255 | Screen for STIs | |
HIV.D.DE256 | Prevent and screen for cervical cancer | |
HIV.D.DE257 | Anal cancer screening (for men who have sex with men) | |
HIV.D.DE258 | Assessment and provision of vaccinations | |
HIV.D.DE259 | Risk factors, comorbidities and coinfections signs and symptoms | |
HIV.D.DE260 | Oral candidiasis | |
HIV.D.DE261 | Vaginal candidiasis | |
HIV.D.DE262 | Cough | |
HIV.D.DE263 | Prolonged fever | |
HIV.D.DE264 | Night sweats | |
HIV.D.DE265 | Weight loss | |
HIV.D.DE266 | Difficulty breathing | |
HIV.D.DE267 | Pneumonia | |
HIV.D.DE268 | Urethral discharge | |
HIV.D.DE269 | Syphilis | |
HIV.D.DE270 | Pelvic inflammatory disease | |
HIV.D.DE271 | Ulcers - skin | |
HIV.D.DE272 | Ulcers - mouth or other | |
HIV.D.DE273 | Ulcers - male genital | |
HIV.D.DE274 | Vaginal discharge | |
HIV.D.DE275 | Malaria | |
HIV.D.DE276 | Chronic obstructive pulmonary disease | |
HIV.D.DE277 | Hypertension | |
HIV.D.DE278 | Diabetes | |
HIV.D.DE279 | Gestational diabetes | |
HIV.D.DE280 | Mental health disorders | |
HIV.D.DE281 | Diarrhoea or abdominal pain | |
HIV.D.DE282 | Presumptive TB | |
HIV.D.DE283 | Severe or complicated malnutrition | |
HIV.D.DE284 | Poor growth or development | |
HIV.D.DE285 | Oedema | |
HIV.D.DE286 | Previously treated for TB | |
HIV.D.DE287 | Other | |
HIV.D.DE288 | Other (specify) | |
HIV.D.DE289 | WHO HIV clinical stage condition or symptom | |
HIV.D.DE290 | Asymptomatic | |
HIV.D.DE291 | Persistent generalized lymphadenopathy | |
HIV.D.DE292 | Moderate unexplained weight loss | |
HIV.D.DE293 | Recurrent respiratory tract infections | |
HIV.D.DE294 | Unexplained persistent hepatosplenomegaly | |
HIV.D.DE295 | Herpes zoster | |
HIV.D.DE296 | Angular cheilitis | |
HIV.D.DE297 | Linear gingival erythema | |
HIV.D.DE298 | Recurrent oral ulceration | |
HIV.D.DE299 | Papular pruritic eruption | |
HIV.D.DE300 | Fungal nail infections | |
HIV.D.DE301 | Seborrhoeic dermatitis | |
HIV.D.DE302 | Extensive wart virus infection | |
HIV.D.DE303 | Extensive molluscum contagiosum | |
HIV.D.DE304 | Unexplained persistent parotid enlargement | |
HIV.D.DE305 | Unexplained severe weight loss in adults | |
HIV.D.DE306 | Unexplained moderate malnutrition not adequately responding to standard therapy | |
HIV.D.DE307 | Unexplained chronic diarrhoea for longer than 1 month | |
HIV.D.DE308 | Unexplained persistent diarrhoea (14 days or more) | |
HIV.D.DE309 | Unexplained persistent fever (above 37.5 C, intermittent or constant, for longer than one 1 month) | |
HIV.D.DE310 | Persistent oral candidiasis | |
HIV.D.DE311 | Oral hairy leukoplakia | |
HIV.D.DE312 | Pulmonary TB | |
HIV.D.DE313 | Lymph node TB | |
HIV.D.DE314 | Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia) | |
HIV.D.DE315 | Severe recurrent bacterial pneumonia | |
HIV.D.DE316 | Acute necrotizing ulcerative stomatitis | |
HIV.D.DE317 | Acute necrotizing ulcerative gingivitis | |
HIV.D.DE318 | Acute necrotizing ulcerative periodontitis | |
HIV.D.DE319 | Unexplained anaemia (<8 g/dL) | |
HIV.D.DE320 | Neutropaenia (<0.5 x 10^9/L) | |
HIV.D.DE321 | Chronic thrombocytopaenia (<50 x 10^9/L) | |
HIV.D.DE322 | Symptomatic lymphoid interstitial pneumonitis | |
HIV.D.DE323 | Chronic HIV-associated lung disease, including bronchiectasis | |
HIV.D.DE324 | HIV wasting syndrome | |
HIV.D.DE325 | Unexplained severe wasting not responding to standard therapy | |
HIV.D.DE326 | Unexplained stunting not responding to standard therapy | |
HIV.D.DE327 | Unexplained severe malnutrition not responding to standard therapy | |
HIV.D.DE328 | Pneumocystis (jirovecii) pneumonia | |
HIV.D.DE329 | Recurrent severe bacterial pneumonia | |
HIV.D.DE330 | Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) | |
HIV.D.DE331 | Empyema | |
HIV.D.DE332 | Pyomyositis | |
HIV.D.DE333 | Bone or joint infection | |
HIV.D.DE334 | Meningitis | |
HIV.D.DE335 | Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month duration or visceral at any site) | |
HIV.D.DE336 | Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month in duration or visceral at any site) | |
HIV.D.DE337 | Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) | |
HIV.D.DE338 | Extrapulmonary TB | |
HIV.D.DE339 | Kaposi sarcoma | |
HIV.D.DE340 | Cytomegalovirus infection (retinitis or infection of other organs) | |
HIV.D.DE341 | Central nervous system toxoplasmosis | |
HIV.D.DE342 | HIV encephalopathy | |
HIV.D.DE343 | Extrapulmonary cryptococcosis, including meningitis | |
HIV.D.DE344 | Disseminated nontuberculous mycobacterial infection | |
HIV.D.DE345 | Progressive multifocal leukoencephalopathy | |
HIV.D.DE346 | Chronic cryptosporidiosis | |
HIV.D.DE347 | Chronic cryptosporidiosis (with diarrhoea) | |
HIV.D.DE348 | Chronic isosporiasis | |
HIV.D.DE349 | Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis) | |
HIV.D.DE350 | Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis) | |
HIV.D.DE351 | Cerebral lymphoma | |
HIV.D.DE352 | B-cell non-Hodgkin lymphoma | |
HIV.D.DE353 | HIV-associated nephropathy or cardiomyopathy | |
HIV.D.DE354 | Recurrent septicaemia (including nontyphoidal Salmonella) | |
HIV.D.DE355 | Invasive cervical carcinoma | |
HIV.D.DE356 | Atypical disseminated leishmaniasis | |
HIV.D.DE357 | Neutropenia | |
HIV.D.DE358 | Clinical stage at start of ART | |
HIV.D.DE359 | WHO clinical stage 1 | |
HIV.D.DE360 | WHO clinical stage 2 | |
HIV.D.DE361 | WHO clinical stage 3 | |
HIV.D.DE362 | WHO clinical stage 4 | |
HIV.D.DE363 | Date of clinical status change | |
HIV.D.DE364 | CD4 count | |
HIV.D.DE365 | CD4 cell percentage | |
HIV.D.DE366 | Date of CD4 count test | |
HIV.D.DE367 | Baseline CD4 count | |
HIV.D.DE368 | Date of baseline CD4 count test | |
HIV.D.DE369 | Late ART initiation | |
HIV.D.DE370 | Reasons for delayed ART initiation | |
HIV.D.DE371 | Patient self-reported as not ready/willing | |
HIV.D.DE372 | Not completed education, support and preparation for ART | |
HIV.D.DE373 | Fear of disclosure | |
HIV.D.DE374 | Patient lacks finances | |
HIV.D.DE375 | Initiated on TB treatment | |
HIV.D.DE376 | Patient initiated on treatment for TB meningitis | |
HIV.D.DE377 | Patient diagnosed with cryptococcal meningitis | |
HIV.D.DE378 | Patient diagnosed with histoplasmosis | |
HIV.D.DE379 | Patient critically/severely ill | |
HIV.D.DE380 | Other | |
HIV.D.DE381 | Other (specify) | |
HIV.D.DE382 | ART initiated within 7 days of diagnosis | |
HIV.D.DE383 | Time to start ART | |
HIV.D.DE384 | Within 7 days of HIV diagnosis | |
HIV.D.DE385 | Within 30 days of HIV diagnosis | |
HIV.D.DE386 | Within 90 days of HIV diagnosis | |
HIV.D.DE387 | Viral load test result | |
HIV.D.DE388 | Virally suppressed | |
HIV.D.DE389 | Date viral load test results received | |
HIV.D.DE390 | Viral load suppression date | |
HIV.D.DE391 | Reason for HIV viral load test | |
HIV.D.DE392 | Routine viral load test | |
HIV.D.DE393 | Targeted viral load monitoring | |
HIV.D.DE394 | Initial viral load test | |
HIV.D.DE395 | Follow-up viral load test after receiving enhanced adherence counselling | |
HIV.D.DE396 | Hepatitis B test required | |
HIV.D.DE397 | Hepatitis C test recommended | |
HIV.D.DE398 | Syphilis test required | |
HIV.D.DE399 | Monitoring examinations | |
HIV.D.DE400 | Haemoglobin (Hb) | |
HIV.D.DE401 | Pregnancy test | |
HIV.D.DE402 | Syphilis test | |
HIV.D.DE403 | Chest X-ray (CXR) | |
HIV.D.DE404 | Sputum or culture for TB | |
HIV.D.DE405 | HBsAg test (HBV) | |
HIV.D.DE406 | HIV viral load test ordered | |
HIV.D.DE407 | HIV viral load test scheduled | |
HIV.D.DE408 | CD4 count ordered | |
HIV.D.DE409 | CD4 count test scheduled | |
HIV.D.DE410 | Cryptococcal antigen test | |
HIV.D.DE411 | Histoplasmosis antigen test | |
HIV.D.DE412 | Cervical cancer screening scheduled | |
HIV.D.DE413 | Date of scheduled monitoring examination | |
HIV.D.DE414 | Hepatitis C test ordered | |
HIV.D.DE415 | Syphilis test ordered | |
HIV.D.DE416 | Received viral load test results | |
HIV.D.DE417 | Date viral load test results received by client | |
HIV.D.DE418 | Reason for ARV drug regimen substitution | |
HIV.D.DE419 | Toxicity/side effects | |
HIV.D.DE420 | Drug-drug interaction | |
HIV.D.DE421 | Pregnancy | |
HIV.D.DE422 | New TB | |
HIV.D.DE423 | New drug available | |
HIV.D.DE424 | Drug out of stock | |
HIV.D.DE425 | Other reason for regimen substitution | |
HIV.D.DE426 | Other reason for regimen substitution (specify) | |
HIV.D.DE427 | Switch to second-line ART regimen recommended | |
HIV.D.DE428 | Switch to third-line ART regimen recommended | |
HIV.D.DE429 | Regimen switch made | |
HIV.D.DE430 | Reason for regimen switch | |
HIV.D.DE431 | Clinical treatment failure | |
HIV.D.DE432 | Immunological failure | |
HIV.D.DE433 | Virological failure | |
HIV.D.DE434 | Other | |
HIV.D.DE435 | Other (specify) | |
HIV.D.DE436 | Regimen substitution recommended | |
HIV.D.DE437 | Dose adjustment recommended | |
HIV.D.DE438 | Regimen substitution made | |
HIV.D.DE439 | Co-trimoxazole prophylaxis start date | |
HIV.D.DE440 | Co-trimoxazole prophylaxis completion date | |
HIV.D.DE441 | Co-trimoxazole prophylaxis dosage | |
HIV.D.DE442 | Co-trimoxazole prophylaxis number of days prescribed | |
HIV.D.DE443 | Suspicion of treatment failure or interruption | |
HIV.D.DE444 | ART regimen prescribed | |
HIV.D.DE445 | Antiretroviral toxicity | |
HIV.D.DE446 | Coinfection status at ART start | |
HIV.D.DE447 | Hepatitis B | |
HIV.D.DE448 | Hepatitis C | |
HIV.D.DE449 | Pregnant and breastfeeding status at ART start | |
HIV.D.DE450 | Pregnant at ART start | |
HIV.D.DE451 | Postpartum at ART start | |
HIV.D.DE452 | ART start at labour and delivery | |
HIV.D.DE453 | Breastfeeding at ART start | |
HIV.D.DE454 | Delivery date of infant | |
HIV.D.DE455 | Serodiscordant partner at ART start | |
HIV.D.DE456 | Regimen start date | |
HIV.D.DE457 | Medications prescribed | |
HIV.D.DE458 | Date medications prescribed | |
HIV.D.DE459 | Dose of medications prescribed | |
HIV.D.DE460 | Number of days medications prescribed | |
HIV.D.DE461 | Medications dispensed | |
HIV.D.DE462 | Number of days of medications dispensed | |
HIV.D.DE463 | Dosage | |
HIV.D.DE464 | Frequency | |
HIV.D.DE465 | Adherence counselling provided | |
HIV.D.DE466 | Type of treatment-limiting toxicity | |
HIV.D.DE467 | Gastrointestinal | |
HIV.D.DE468 | Skin issues | |
HIV.D.DE469 | Peripheral neuropathy | |
HIV.D.DE470 | Central nervous system symptoms | |
HIV.D.DE471 | Weight gain | |
HIV.D.DE472 | Hepatic dysfunction | |
HIV.D.DE473 | Haematological disorders | |
HIV.D.DE474 | Fatigue | |
HIV.D.DE475 | Headache | |
HIV.D.DE476 | Bone dysfunction | |
HIV.D.DE477 | Metabolic symptoms | |
HIV.D.DE478 | Kidney dysfunction | |
HIV.D.DE479 | Unexpected adverse drug reaction | |
HIV.D.DE480 | Unexpected adverse drug reaction (specify) | |
HIV.D.DE481 | Date(s) of substitution within first-line regimen | |
HIV.D.DE482 | Reason(s) for substitution within first-line regimen | |
HIV.D.DE483 | New antiretroviral regimen after substitution within first-line regimen | |
HIV.D.DE484 | Date of switch to second-line regimen | |
HIV.D.DE485 | New regimen after switch to second-line regimen | |
HIV.D.DE486 | Reason for switch to second-line regimen | |
HIV.D.DE487 | Date(s) of substitution within second-line regimen | |
HIV.D.DE488 | Reason(s) for substitution within second-line regimen | |
HIV.D.DE489 | New regimen(s) after substitution within second-line regimen | |
HIV.D.DE490 | Date of switch to third-line regimen | |
HIV.D.DE491 | New regimen after switch to third-line regimen | |
HIV.D.DE492 | Reason for switch to third-line regimen | |
HIV.D.DE493 | Date(s) of substitution within third-line regimen | |
HIV.D.DE494 | Reason(s) for substitution within third-line regimen | |
HIV.D.DE495 | New regimen(s) after substitution within third-line regimen | |
HIV.D.DE496 | Enhanced adherence counselling provided | |
HIV.D.DE497 | First enhanced adherence counselling session completed | |
HIV.D.DE498 | Date of first enhanced adherence counselling session completed | |
HIV.D.DE499 | Second enhanced adherence counselling session completed | |
HIV.D.DE500 | Date of second enhanced adherence counselling session completed | |
HIV.D.DE501 | Third enhanced adherence counselling session completed | |
HIV.D.DE502 | Date of third enhanced adherence counselling session completed | |
HIV.D.DE503 | Name of treatment supporter | |
HIV.D.DE504 | Address of treatment supporter | |
HIV.D.DE505 | Telephone number of treatment supporter | |
HIV.D.DE506 | Home-based care provider | |
HIV.D.DE507 | Counselling provided on diagnoses | |
HIV.D.DE508 | Hepatitis B positive counselling conducted | |
HIV.D.DE509 | Hepatitis C positive counselling conducted | |
HIV.D.DE510 | Syphilis counselling and treatment | |
HIV.D.DE511 | Syphilis counselling, treatment and further testing | |
HIV.D.DE512 | Accepted partner services | |
HIV.D.DE513 | HIV testing for partners and biological children | |
HIV.D.DE514 | HIV status of family member | |
HIV.D.DE515 | Unique ID of family member | |
HIV.D.DE516 | Date of death of family member | |
HIV.D.DE517 | Offered voluntary partner services | |
HIV.D.DE518 | Provided support for disclosure and partner services | |
HIV.D.DE519 | Other support services | |
HIV.D.DE520 | Mental health services | |
HIV.D.DE521 | Psychosocial counselling, support and treatment adherence counselling | |
HIV.D.DE522 | Legal and social services | |
HIV.D.DE523 | Services for responding to violence against women | |
HIV.D.DE524 | Date/time of follow-up appointment | |
HIV.D.DE525 | Type of follow-up appointment | |
HIV.D.DE526 | Clinical visit | |
HIV.D.DE527 | Antiretroviral drug pick up | |
HIV.D.DE528 | Post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer | |
HIV.D.DE529 | Other | |
HIV.D.DE530 | Other (specify) | |
HIV.D.DE531 | Follow-up test recommended date | |
HIV.D.DE532 | Reason blood pressure reading not done | |
HIV.D.DE533 | BP cuff (sphygmomanometer) not available | |
HIV.D.DE534 | BP cuff (sphygmomanometer) is broken | |
HIV.D.DE535 | Other | |
HIV.D.DE536 | Other (specify) | |
HIV.D.DE537 | Current medications | |
HIV.D.DE538 | No medications | |
HIV.D.DE539 | Don't know of any current medications | |
HIV.D.DE540 | Analgesic | |
HIV.D.DE541 | Antacids | |
HIV.D.DE542 | Antibiotics (broad-spectrum) | |
HIV.D.DE543 | Anticonvulsive | |
HIV.D.DE544 | Antidiabetic | |
HIV.D.DE545 | Antifungals | |
HIV.D.DE546 | Antihelmintic | |
HIV.D.DE547 | Antihypertensive | |
HIV.D.DE548 | Antimalarials | |
HIV.D.DE549 | Antiretrovirals (ARVs) | |
HIV.D.DE550 | Antiparasitics | |
HIV.D.DE551 | Antivirals | |
HIV.D.DE552 | Buprenorphine | |
HIV.D.DE553 | Co-trimoxazole preventive therapy (CPT) | |
HIV.D.DE554 | Hormonal family planning method | |
HIV.D.DE555 | Methadone | |
HIV.D.DE556 | PrEP to prevent HIV | |
HIV.D.DE557 | Other antibiotics | |
HIV.D.DE558 | Other medications | |
HIV.D.DE559 | Other medications (specify) | |
HIV.D.DE560 | Allergies | |
HIV.D.DE561 | No known allergies | |
HIV.D.DE562 | Don't know of any allergies | |
HIV.D.DE563 | Albendazole | |
HIV.D.DE564 | Malaria medication (sulfadoxine-pyrimethamine) | |
HIV.D.DE565 | Penicillin | |
HIV.D.DE566 | Tenofovir disoproxil fumarate (TDF) | |
HIV.D.DE567 | Other allergies | |
HIV.D.DE568 | Other allergies (specify) | |
HIV.D.DE569 | Family planning method used | |
HIV.D.DE570 | Copper-bearing intrauterine device (Cu-IUD) | |
HIV.D.DE571 | Levonorgestrel intrauterine device (LNG-IUD) | |
HIV.D.DE572 | Etonogestrel (ETG) one-rod implant | |
HIV.D.DE573 | Levonorgestrel (LNG) two-rod implant | |
HIV.D.DE574 | DMPA-IM | |
HIV.D.DE575 | DMPA-SC | |
HIV.D.DE576 | NET-EN norethisterone enanthate | |
HIV.D.DE577 | Progestogen-only pills (POP) | |
HIV.D.DE578 | Combined oral contraceptives (COCs) | |
HIV.D.DE579 | Combined contraceptive patch | |
HIV.D.DE580 | Combined contraceptive vaginal ring (CVR) | |
HIV.D.DE581 | Progesterone-releasing vaginal ring (PVR) | |
HIV.D.DE582 | Lactational amenorrhea method (LAM) | |
HIV.D.DE583 | Emergency contraceptive pills (ECPs) | |
HIV.D.DE584 | Fertility awareness-based methods (FAB) | |
HIV.D.DE585 | Male condoms | |
HIV.D.DE586 | Female condoms | |
HIV.D.DE587 | Withdrawal | |
HIV.D.DE588 | Female relying on male method | |
HIV.D.DE589 | Male relying on female method | |
HIV.D.DE590 | Male sterilization | |
HIV.D.DE591 | Female sterilization | |
HIV.D.DE592 | No method | |
HIV.D.DE593 | Medication status | |
HIV.D.DE594 | Currently taking | |
HIV.D.DE595 | Completed | |
HIV.D.DE596 | Entered in error | |
HIV.D.DE597 | Intended | |
HIV.D.DE598 | Stopped | |
HIV.D.DE599 | On hold | |
HIV.D.DE600 | Unknown | |
HIV.D.DE601 | Did not take | |
HIV.D.DE602 | Hepatitis B negative counselling conducted | |
HIV.D.DE603 | Vaccine brand | |
HIV.D.DE604 | Vaccine type | |
HIV.D.DE605 | Date and time of vaccination | |
HIV.D.DE606 | Vaccination location | |
HIV.D.DE607 | Dose number | |
HIV.D.DE608 | Dose quantity | |
HIV.D.DE609 | Total doses in series | |
HIV.D.DE610 | Disease targeted | |
HIV.D.DE611 | Hepatitis A | |
HIV.D.DE612 | Hepatitis B | |
HIV.D.DE613 | Tetanus | |
HIV.D.DE614 | COVID-19 | |
HIV.D.DE615 | Influenza due to influenza B virus | |
HIV.D.DE616 | Tuberculosis | |
HIV.D.DE617 | Acute poliomyelitis | |
HIV.D.DE618 | Measles | |
HIV.D.DE619 | Diptheria | |
HIV.D.DE620 | Rabies | |
HIV.D.DE621 | Cholera | |
HIV.D.DE622 | Mumps | |
HIV.D.DE623 | HPV infection | |
HIV.D.DE624 | Haemophilus influenzae type B | |
HIV.D.DE625 | Varicella | |
HIV.D.DE626 | Dengue | |
HIV.D.DE627 | Yellow fever | |
HIV.D.DE628 | Japanese Encephalitis | |
HIV.D.DE629 | Rubella | |
HIV.D.DE630 | Pertussis | |
HIV.D.DE631 | Enteritis due to rotavirus | |
HIV.D.DE632 | Pneumococcal disease | |
HIV.D.DE633 | Meningococcal disease | |
HIV.D.DE634 | Tick-borne encephalitis | |
HIV.D.DE635 | Typhoid | |
HIV.D.DE636 | Reason immunization was not provided | |
HIV.D.DE637 | Stock-out | |
HIV.D.DE638 | Client is ill | |
HIV.D.DE639 | Client refused | |
HIV.D.DE640 | Allergy to vaccine | |
HIV.D.DE641 | Other reason immunization not provided | |
HIV.D.DE642 | Other reason immunization not provided (specify) | |
HIV.D.DE643 | Malaria prophylaxis | |
HIV.D.DE644 | IPTp-SP dose number provided | |
HIV.D.DE645 | Date IPTp-SP dose provided | |
HIV.D.DE646 | Reason malaria prophylaxis not provided | |
HIV.D.DE647 | Client was referred | |
HIV.D.DE648 | Stock out | |
HIV.D.DE649 | Expired | |
HIV.D.DE650 | Other reason not provided | |
HIV.D.DE651 | Other reason not provided (specify) | |
HIV.D.DE652 | >28 days since last missed appointment | |
HIV.D.DE653 | AIDS-related death | |
HIV.D.DE654 | Date of first AIDS diagnosis | |
HIV.D.DE655 | Age at final HPV vaccination dose received | |
HIV.D.DE656 | Date of cervical cancer screening test | |
HIV.D.DE657 | Lifetime screening test number | |
HIV.D.DE658 | Cervical cancer primary screening test type | |
HIV.D.DE659 | HPV-DNA | |
HIV.D.DE660 | VIA | |
HIV.D.DE661 | Cervical cytology | |
HIV.D.DE662 | Other | |
HIV.D.DE663 | Other (specify) | |
HIV.D.DE664 | HPV-DNA cervical cancer screening test result | |
HIV.D.DE665 | Negative | |
HIV.D.DE666 | Positive | |
HIV.D.DE667 | Invalid | |
HIV.D.DE668 | VIA cervical cancer screening test result | |
HIV.D.DE669 | Negative | |
HIV.D.DE670 | Positive | |
HIV.D.DE671 | Suspected cancer | |
HIV.D.DE672 | Invalid | |
HIV.D.DE673 | Cervical cytology screening test result | |
HIV.D.DE674 | NILM | |
HIV.D.DE675 | ASCUS | |
HIV.D.DE676 | LSIL | |
HIV.D.DE677 | HSIL | |
HIV.D.DE678 | Cancer | |
HIV.D.DE679 | Invalid/inadequate | |
HIV.D.DE680 | Cervical cancer triage test date | |
HIV.D.DE681 | Cervical cancer triage test type | |
HIV.D.DE682 | VIA | |
HIV.D.DE683 | Colposcopy | |
HIV.D.DE684 | Cervical cytology | |
HIV.D.DE685 | HPV16/18 | |
HIV.D.DE686 | Other | |
HIV.D.DE687 | Other (specify) | |
HIV.D.DE688 | HPV16/18 test result | |
HIV.D.DE689 | Positive | |
HIV.D.DE690 | Negative | |
HIV.D.DE691 | Cervical cancer colposcopy result | |
HIV.D.DE692 | Normal colposcopic findings | |
HIV.D.DE693 | Abnormal colposcopic findings | |
HIV.D.DE694 | Suspicious for invasive cervical cancer | |
HIV.D.DE695 | Miscellaneous findings | |
HIV.D.DE696 | Inadequate | |
HIV.D.DE697 | Cervical cancer histopathology result | |
HIV.D.DE698 | Normal | |
HIV.D.DE699 | LSIL (inclusive of LSIL-CIN1) | |
HIV.D.DE700 | HSIL (inclusive of HSIL-CIN2 or HSIL-CIN3) | |
HIV.D.DE701 | Invasive cervical cancer | |
HIV.D.DE702 | Date of additional cervical cancer triage test | |
HIV.D.DE703 | Additional cervical cancer triage test type (specify) | |
HIV.D.DE704 | Additional cervical cancer triage test result (specify) | |
HIV.D.DE705 | Date of diagnosis of cervical precancer lesions or invasive cervical cancer | |
HIV.D.DE706 | Cervical cancer screening outcome | |
HIV.D.DE707 | Positive for cervical precancer lesions | |
HIV.D.DE708 | Negative for cervical precancer lesions | |
HIV.D.DE709 | Cervical cancer diagnosis | |
HIV.D.DE710 | Cervical precancer lesions | |
HIV.D.DE711 | Invasive cervical cancer | |
HIV.D.DE712 | Cervical cancer stage at diagnosis | |
HIV.D.DE713 | Stage 0 | |
HIV.D.DE714 | Stage I | |
HIV.D.DE715 | Stage II | |
HIV.D.DE716 | Stage III | |
HIV.D.DE717 | Stage IV | |
HIV.D.DE718 | Date of treatment for cervical precancer lesions | |
HIV.D.DE719 | Treatment method for cervical precancer lesions | |
HIV.D.DE720 | Cryotherapy | |
HIV.D.DE721 | Thermal ablation | |
HIV.D.DE722 | Laser ablation | |
HIV.D.DE723 | CKC | |
HIV.D.DE724 | Laser cone biopsy | |
HIV.D.DE725 | LLETZ/LEEP | |
HIV.D.DE726 | Other | |
HIV.D.DE727 | Other (specify) | |
HIV.D.DE728 | Date of follow-up for treatment for cervical precancer lesions | |
HIV.D.DE729 | Date of start of invasive cancer treatment | |
HIV.D.DE730 | Invasive cervical cancer treatment episode | |
HIV.D.DE731 | Invasive cervical cancer treatment method | |
HIV.D.DE732 | Conization | |
HIV.D.DE733 | Trachelectomy | |
HIV.D.DE734 | Hysterectomy | |
HIV.D.DE735 | Management of invasive cervical cancer | |
HIV.D.DE736 | Radiotherapy | |
HIV.D.DE737 | Chemotherapy | |
HIV.D.DE738 | Chemoradiation | |
HIV.D.DE739 | Other | |
HIV.D.DE740 | Other (specify) | |
HIV.D.DE741 | Treatment outcome | |
HIV.D.DE742 | Secondary/other cancers diagnosed | |
HIV.D.DE743 | Cancers at other sites (HPV- and non-HPV related) | |
HIV.D.DE744 | Date of death | |
HIV.D.DE745 | Cervical cancer screening interval amongst WLHIV | |
HIV.D.DE746 | Entry point for facility-level testing | |
HIV.D.DE747 | Provider-initiated tested in a clinic or emergency facility | |
HIV.D.DE748 | Antenatal care clinic | |
HIV.D.DE749 | Voluntary counselling and testing (within a health facility setting) | |
HIV.D.DE750 | Family planning clinic | |
HIV.D.DE751 | Other facility-level testing | |
HIV.D.DE752 | Tuberculosis (TB) clinic | |
HIV.D.DE753 | Offer other clinical services | |
HIV.D.DE754 | Assessment and provision of vaccinations | |
HIV.D.DE755 | Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment | |
HIV.D.DE756 | Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia | |
HIV.D.DE757 | Intensified TB case finding and linkage to TB treatment | |
HIV.D.DE758 | Provision of isoniazid preventive therapy if person does not have TB | |
HIV.D.DE759 | Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology | |
HIV.D.DE760 | Eligible for DSD ART | |
HIV.D.DE761 | Date DSD ART eligibility assessed | |
HIV.D.DE762 | Currently enrolled in DSD ART model | |
HIV.D.DE763 | DSD ART start date | |
HIV.D.DE764 | DSD ART model(s) | |
HIV.D.DE765 | Fast track ART refill | |
HIV.D.DE766 | Facility adherence club | |
HIV.D.DE767 | Community ART distribution point | |
HIV.D.DE768 | CHW/peer educator community ART group | |
HIV.D.DE769 | Patient/client community ART group | |
HIV.D.DE770 | Other DSD ART model | |
HIV.D.DE771 | Other DSD ART model (specify) | |
HIV.D.DE772 | Partner testing offered | |
HIV.D.DE773 | Partner testing accepted | |
HIV.D.DE774 | Date partner contacted for index testing | |
HIV.D.DE775 | Date partner tested for HIV | |
HIV.D.DE776 | Date of next scheduled follow-up appointment | |
HIV.D.DE777 | Type of next follow-up appointment | |
HIV.D.DE778 | Syndrome/STI diagnosed | |
HIV.D.DE779 | Urethral discharge syndrome | |
HIV.D.DE780 | Vaginal discharge syndrome | |
HIV.D.DE781 | Lower Abdominal pain | |
HIV.D.DE782 | Genital ulcer disease syndrome | |
HIV.D.DE783 | Anorectal discharge | |
HIV.D.DE784 | Sent for testing | |
HIV.D.DE785 | Other | |
HIV.D.DE786 | Other (specify) | |
HIV.D.DE787 | Any STI syndrome diagnosed | |
HIV.D.DE788 | Date of STI test | |
HIV.D.DE789 | STI tested for | |
HIV.D.DE790 | Neisseria gonorrhoeae | |
HIV.D.DE791 | Chlamydia trachomatis | |
HIV.D.DE792 | Trichomonas vaginalis | |
HIV.D.DE793 | Syphilis (Treponema pallidum) | |
HIV.D.DE794 | Herpes simplex virus (HSV1, HSV2) | |
HIV.D.DE795 | Mycoplasma genitalium | |
HIV.D.DE796 | Mpox | |
HIV.D.DE797 | Hepatitis B | |
HIV.D.DE798 | Hepatitis C | |
HIV.D.DE799 | Other | |
HIV.D.DE800 | Other (specify) | |
HIV.D.DE801 | Syphilis test date | |
HIV.D.DE802 | Syphilis test result | |
HIV.D.DE803 | Positive | |
HIV.D.DE804 | Negative | |
HIV.D.DE805 | Inconclusive | |
HIV.D.DE806 | Syphilis treatment start date | |
HIV.D.DE807 | Gonorrhoea test date | |
HIV.D.DE808 | Gonorrhoea test result | |
HIV.D.DE809 | Positive | |
HIV.D.DE810 | Negative | |
HIV.D.DE811 | Inconclusive | |
HIV.D.DE812 | Gonorrhoea treatment start date | |
HIV.D.DE813 | Type of specimen | |
HIV.D.DE814 | Blood | |
HIV.D.DE815 | Urine | |
HIV.D.DE816 | Cervical or vaginal swab | |
HIV.D.DE817 | Urethral or penile swab | |
HIV.D.DE818 | Rectal swab | |
HIV.D.DE819 | Other | |
HIV.D.DE820 | Other type of specimen (specify) | |
HIV.D.DE821 | Syphilis test type | |
HIV.D.DE822 | Treponemal | |
HIV.D.DE823 | Non-treponemal | |
HIV.D.DE824 | POC Test | |
HIV.D.DE825 | NAAT | |
HIV.D.DE826 | Other | |
HIV.D.DE827 | Other syphilis test type (specify) | |
HIV.D.DE828 | Neisseria gonorrhoeae test type | |
HIV.D.DE829 | NAAT | |
HIV.D.DE830 | POC Test | |
HIV.D.DE831 | Culture | |
HIV.D.DE832 | Microscopy | |
HIV.D.DE833 | Other | |
HIV.D.DE834 | Other (specify) | |
HIV.D.DE835 | POC Test for Neisseria gonorrhoeae (specify) | |
HIV.D.DE836 | Chlamydia trachomatis test type | |
HIV.D.DE837 | NAAT | |
HIV.D.DE838 | POC Test | |
HIV.D.DE839 | Culture | |
HIV.D.DE840 | ELISA | |
HIV.D.DE841 | Microscopy | |
HIV.D.DE842 | Other | |
HIV.D.DE843 | Other test for Chlamydia (specify) | |
HIV.D.DE844 | POC Test type for Chlamydia test (specify) | |
HIV.D.DE845 | Trichomonas vaginalis test type | |
HIV.D.DE846 | NAAT | |
HIV.D.DE847 | POC Test | |
HIV.D.DE848 | Culture | |
HIV.D.DE849 | Microscopy | |
HIV.D.DE850 | Other | |
HIV.D.DE851 | Other (specify) | |
HIV.D.DE852 | POC Test type for Trichomonas vaginalis test (specify) | |
HIV.D.DE853 | Herpes simplex virus (HSV) test type | |
HIV.D.DE854 | NAAT | |
HIV.D.DE855 | Antibody test | |
HIV.D.DE856 | Other | |
HIV.D.DE857 | Other (specify) | |
HIV.D.DE858 | Mycoplasma genitalium test type | |
HIV.D.DE859 | NAAT | |
HIV.D.DE860 | Microscopy | |
HIV.D.DE861 | Other | |
HIV.D.DE862 | Other (specify) | |
HIV.D.DE863 | Test type for other STI tested for (specify) | |
HIV.D.DE864 | STI test result | |
HIV.D.DE865 | Positive | |
HIV.D.DE866 | Negative | |
HIV.D.DE867 | Inconclusive | |
HIV.D.DE868 | Date of STI confirmatory test | |
HIV.D.DE869 | Confirmatory syphilis test type | |
HIV.D.DE870 | Treponemal | |
HIV.D.DE871 | Non-treponemal | |
HIV.D.DE872 | POC Test | |
HIV.D.DE873 | NAAT | |
HIV.D.DE874 | Other | |
HIV.D.DE875 | Other (specify) | |
HIV.D.DE876 | Confirmatory test type for other STI (specify) | |
HIV.D.DE877 | Confirmatory STI test result | |
HIV.D.DE878 | Positive | |
HIV.D.DE879 | Negative | |
HIV.D.DE880 | Inconclusive | |
HIV.D.DE881 | Date STI treatment prescribed | |
HIV.D.DE882 | Date STI treatment dispensed | |
HIV.D.DE883 | STI treatment dispensed (specify) | |
HIV.D.DE884 | Mid-upper arm circumference (MUAC) | |
HIV.D.DE885 | Date of start of fluconazole prophylaxis | |
HIV.D.DE886 | Fluconazole prophylaxis | |
HIV.D.DE887 | Date started cryptococcal meningitis treatment induction regimen | |
HIV.D.DE888 | Date completed cryptococcal meningitis treatment induction regimen | |
HIV.D.DE889 | Date started cryptococcal meningitis treatment maintenance regimen | |
HIV.D.DE890 | Date completed cryptococcal meningitis treatment maintenance regimen | |
HIV.D.DE891 | Date started cryptococcal meningitis treatment consolidation regimen | |
HIV.D.DE892 | Date completed cryptococcal meningitis treatment consolidation regimen | |
HIV.D.DE893 | Staging of liver disease | |
HIV.D.DE894 | F0-4, fibrosis staging | |
HIV.D.DE895 | F4 or cirrhosis, presence of cirrhosis | |
HIV.D.DE896 | Advanced HIV disease | |
HIV.D.DE897 | WHO functional status | |
HIV.D.DE898 | Working, able to perform usual work inside and outside the home | |
HIV.D.DE899 | Ambulatory, able to perform activity of daily living (ADL), not able to work | |
HIV.D.DE900 | Bedridden not able to perform ADL | |
HIV.D.DE901 | Tailored adherence counselling for advanced HIV disease | |
HIV.D.DE902 | Date(s) of tracing interventions | |
HIV.D.DE903 | Medication/drug | |
HIV.D.DE904 | Rifampicin | |
HIV.D.DE905 | Halofantrine | |
HIV.D.DE906 | Lovastatin | |
HIV.D.DE907 | Simvastatin | |
HIV.D.DE908 | Hormonal contraception | |
HIV.D.DE909 | Metformin | |
HIV.D.DE910 | Astemizole | |
HIV.D.DE911 | Terfenadine | |
HIV.D.DE912 | TDF | |
HIV.D.DE913 | Simeprevir | |
HIV.D.DE914 | Ombitasvir + paritaprevir/ritonavir + dasabuvir | |
HIV.D.DE915 | Methadone | |
HIV.D.DE916 | Buprenorphine | |
HIV.D.DE917 | Dofetilide | |
HIV.D.DE918 | Carbamazepine | |
HIV.D.DE919 | Phenobarbital | |
HIV.D.DE920 | Phenytoin | |
HIV.D.DE921 | Polyvalent cation products containing Mg, Al, Fe, Ca and Zn | |
HIV.D.DE922 | Amodiaquine | |
HIV.D.DE923 | Cisapride | |
HIV.D.DE924 | Ergotamine | |
HIV.D.DE925 | Dihydroergotamine | |
HIV.D.DE926 | Midazolam | |
HIV.D.DE927 | Triazolam | |
HIV.D.DE928 | Estrogen-based hormonal contraception | |
HIV.D.DE929 | Ribavirin | |
HIV.D.DE930 | Peginterferon alfa-2a | |
HIV.D.DE931 | Other | |
HIV.D.DE932 | Other (specify) | |
HIV.D.DE933 | Medication change recommended | |
HIV.D.DE934 | WHO HIV clinical stage condition or symptom | |
HIV.D.DE935 | Pulmonary TB | |
HIV.D.DE936 | Lymph node TB | |
HIV.D.DE937 | Extrapulmonary TB | |
HIV.D.DE938 | TB disease | |
HIV.D.DE939 | TB diagnosis result | |
HIV.D.DE940 | Diagnosed TB | |
HIV.D.DE941 | TB excluded | |
HIV.D.DE942 | Method of TB diagnosis | |
HIV.D.DE943 | Bacteriologically confirmed | |
HIV.D.DE944 | Clinically diagnosed | |
HIV.D.DE945 | Presumptive TB | |
HIV.D.DE946 | Presumptive TB registration date | |
HIV.D.DE947 | TB treatment history | |
HIV.D.DE948 | New | |
HIV.D.DE949 | Recurrent | |
HIV.D.DE950 | Re-registered | |
HIV.D.DE951 | Unknown | |
HIV.D.DE952 | Date of TB diagnosis | |
HIV.D.DE953 | Currently on TB preventive treatment (TPT) | |
HIV.D.DE954 | TB preventive treatment (TPT) start date | |
HIV.D.DE955 | TB preventive treatment (TPT) completion date | |
HIV.D.DE956 | TB screening algorithm | |
HIV.D.DE957 | Screening with cough | |
HIV.D.DE958 | Screening with any TB symptom | |
HIV.D.DE959 | W4SS single screening algorithm | |
HIV.D.DE960 | CRP single screening algorithm | |
HIV.D.DE961 | CXR single screening algorithm | |
HIV.D.DE962 | Parallel screening algorithm with W4SS and CRP | |
HIV.D.DE963 | Sequential positive screening algorithm with W4SS and CRP | |
HIV.D.DE964 | Sequential negative screening algorithm with W4SS and CRP | |
HIV.D.DE965 | Parallel screening algorithm with W4SS and CXR | |
HIV.D.DE966 | Sequential positive screening algorithm with W4SS and CXR | |
HIV.D.DE967 | Sequential negative screening algorithm with W4SS and CXR | |
HIV.D.DE968 | Screening with mWRD | |
HIV.D.DE969 | Clinical assessment | |
HIV.D.DE970 | Other TB screening algorithm | |
HIV.D.DE971 | Other TB screening algorithm (specify) | |
HIV.D.DE972 | TB screening conducted | |
HIV.D.DE973 | Symptoms of TB | |
HIV.D.DE974 | Current cough | |
HIV.D.DE975 | Prolonged cough (>=2w) | |
HIV.D.DE976 | Fever of 39 °C or greater | |
HIV.D.DE977 | Weight loss (reported) | |
HIV.D.DE978 | Night sweats | |
HIV.D.DE979 | Poor weight gain | |
HIV.D.DE980 | Reduced playfulness | |
HIV.D.DE981 | Chest pain | |
HIV.D.DE982 | Haemoptysis | |
HIV.D.DE983 | Lethargy | |
HIV.D.DE984 | | |
HIV.D.DE985 | History of contact with a person with TB | |
HIV.D.DE986 | TB screening result | |
HIV.D.DE987 | Screen positive for TB | |
HIV.D.DE988 | Screen negative for TB | |
HIV.D.DE989 | Inconclusive | |
HIV.D.DE990 | TB screening date | |
HIV.D.DE991 | TB screening result date | |
HIV.D.DE992 | TB diagnostic test category | |
HIV.D.DE993 | LF-LAM | |
HIV.D.DE994 | mWRD test for TB | |
HIV.D.DE995 | Microscopy - Sputum acid-fast bacilli (AFB) | |
HIV.D.DE996 | TB Culture | |
HIV.D.DE997 | TB diagnostic test date | |
HIV.D.DE998 | Test sample collection date | |
HIV.D.DE999 | TB diagnostic test result date | |
HIV.D.DE1000 | TB treatment started | |
HIV.D.DE1001 | TB treatment start date | |
HIV.D.DE1002 | TB treatment outcome | |
HIV.D.DE1003 | Treatment failed | |
HIV.D.DE1004 | Cured | |
HIV.D.DE1005 | Treatment completed | |
HIV.D.DE1006 | Died | |
HIV.D.DE1007 | Lost to follow-up | |
HIV.D.DE1008 | Not evaluated | |
HIV.D.DE1009 | TB treatment completion date | |
HIV.D.DE1010 | TB treatment regimen composition | |
HIV.D.DE1011 | Isoniazid | |
HIV.D.DE1012 | Rifampicin | |
HIV.D.DE1013 | Rifabutin | |
HIV.D.DE1014 | Ethambutol | |
HIV.D.DE1015 | Levofloxacin | |
HIV.D.DE1016 | Pyrazinamide | |
HIV.D.DE1017 | Eligible for TB preventive treatment | |
HIV.D.DE1018 | Date when eligibility for TB preventive treatment (TPT) was determined | |
HIV.D.DE1019 | TB status at ART start | |
HIV.D.DE1020 | Symptomatic for TB | |
HIV.D.DE1021 | Diagnosed TB | |
HIV.D.DE1022 | | |
HIV.D.DE1023 | TB prevention services accepted | |
HIV.D.DE1024 | TB meningitis | |
HIV.D.DE1025 | C reactive protein test date | |
HIV.D.DE1026 | C reactive protein test result | |
HIV.D.DE1027 | C reactive protein test result date | |
HIV.D.DE1028 | TPT regimen type | |
HIV.D.DE1029 | 3HP | |
HIV.D.DE1030 | 1HP | |
HIV.D.DE1031 | 6H | |
HIV.D.DE1032 | Six months of levofloxacin daily | |
HIV.D.DE1033 | Other TB preventive treatment (TPT) regimen | |
HIV.D.DE1034 | TB preventive treatment (TPT) status | |
HIV.D.DE1035 | Not started | |
HIV.D.DE1036 | On TPT | |
HIV.D.DE1037 | On TPT with interruptions | |
HIV.D.DE1038 | On hold | |
HIV.D.DE1039 | Completed | |
HIV.E.DE1 | Pregnant woman's first name | |
HIV.E.DE2 | Pregnant woman's surname | |
HIV.E.DE3 | Pregnant woman's unique ID | |
HIV.E.DE4 | Antenatal care number | |
HIV.E.DE5 | Gestational age | |
HIV.E.DE6 | Source of gestational age | |
HIV.E.DE7 | Last menstrual period (LMP) | |
HIV.E.DE8 | Ultrasound | |
HIV.E.DE9 | Symphysis fundal height (SFH) or abdominal palpation | |
HIV.E.DE10 | Expected date of delivery (EDD) | |
HIV.E.DE11 | Number of pregnancies (gravida) | |
HIV.E.DE12 | Number of previous pregnancies | |
HIV.E.DE13 | Number of miscarriages and/or abortions | |
HIV.E.DE14 | Number of live births | |
HIV.E.DE15 | Number of caesarian sections | |
HIV.E.DE16 | Number of stillbirths | |
HIV.E.DE17 | Past pregnancy complications | |
HIV.E.DE18 | No past pregnancy complications | |
HIV.E.DE19 | Does not know of any past pregnancy complications | |
HIV.E.DE20 | Pre-eclampsia | |
HIV.E.DE21 | Eclampsia | |
HIV.E.DE22 | Alcohol use | |
HIV.E.DE23 | Baby died within 24 hours of birth | |
HIV.E.DE24 | Prolonged labour | |
HIV.E.DE25 | Convulsions | |
HIV.E.DE26 | Forceps | |
HIV.E.DE27 | Gestational diabetes mellitus | |
HIV.E.DE28 | Heavy bleeding (during or after delivery) | |
HIV.E.DE29 | Macrosomia | |
HIV.E.DE30 | Perineal tear (3rd or 4th degree) | |
HIV.E.DE31 | Substance use | |
HIV.E.DE32 | Tobacco use | |
HIV.E.DE33 | Vacuum delivery | |
HIV.E.DE34 | Other past pregnancy problems | |
HIV.E.DE35 | Other past pregnancy problems (specify) | |
HIV.E.DE36 | Parity | |
HIV.E.DE37 | Pregnancy in HIV-infected woman | |
HIV.E.DE38 | Date new pregnancy of HIV-positive woman identified | |
HIV.E.DE39 | ANC contact during pregnancy | |
HIV.E.DE40 | Date of first ANC visit | |
HIV.E.DE41 | Timing of ART initiation | |
HIV.E.DE42 | Already on ART at first antenatal care visit | |
HIV.E.DE43 | Newly on ART during pregnancy | |
HIV.E.DE44 | Newly on ART during labour and delivery | |
HIV.E.DE45 | Maternal use of recommended ART regimen | |
HIV.E.DE46 | Delivery date | |
HIV.E.DE47 | Pregnancy outcome | |
HIV.E.DE48 | Live birth | |
HIV.E.DE49 | Early fetal loss/miscarriage | |
HIV.E.DE50 | Induced abortion | |
HIV.E.DE51 | Stillbirth | |
HIV.E.DE52 | Delivery mode | |
HIV.E.DE53 | Spontaneous vaginal delivery | |
HIV.E.DE54 | Assisted vaginal delivery | |
HIV.E.DE55 | Caesarian section (C/S, operative delivery) | |
HIV.E.DE56 | Indications for caesarian section (C/S) | |
HIV.E.DE57 | Obstetric complications | |
HIV.E.DE58 | Live birth | |
HIV.E.DE59 | Live birth to an HIV-positive woman | |
HIV.E.DE60 | Gestational age at birth | |
HIV.E.DE61 | Small for gestational age (SGA) | |
HIV.E.DE62 | Preterm birth status | |
HIV.E.DE63 | Not preterm | |
HIV.E.DE64 | Preterm (<37 weeks gestation) | |
HIV.E.DE65 | Very preterm (<32 weeks gestation) | |
HIV.E.DE66 | Maternal ART start date | |
HIV.E.DE67 | Place of delivery | |
HIV.E.DE68 | Health facility | |
HIV.E.DE69 | Home | |
HIV.E.DE70 | Other | |
HIV.E.DE71 | Other (specify) | |
HIV.E.DE72 | Delivery facility | |
HIV.E.DE73 | Date of miscarriage or abortion | |
HIV.E.DE74 | Date of death of mother | |
HIV.E.DE75 | Cause of death of mother | |
HIV.E.DE76 | Infant's first name | |
HIV.E.DE77 | Infant's surname | |
HIV.E.DE78 | Infant's unique ID | |
HIV.E.DE79 | Mother's first name | |
HIV.E.DE80 | Mother's surname | |
HIV.E.DE81 | Mother's unique ID | |
HIV.E.DE82 | Caregiver's first name | |
HIV.E.DE83 | Caregiver's surname | |
HIV.E.DE84 | Caregiver's unique identifier | |
HIV.E.DE85 | ANC contact date | |
HIV.E.DE86 | Referral | |
HIV.E.DE87 | Infant date of birth | |
HIV.E.DE88 | Date of birth of infant unknown | |
HIV.E.DE89 | Estimated age of infant | |
HIV.E.DE90 | Age of infant | |
HIV.E.DE91 | Gender of infant | |
HIV.E.DE92 | Female | |
HIV.E.DE93 | Male | |
HIV.E.DE94 | Other | |
HIV.E.DE95 | Infant height | |
HIV.E.DE96 | Infant weight | |
HIV.E.DE97 | Birth weight | |
HIV.E.DE98 | Low birth weight | |
HIV.E.DE99 | Length of infant | |
HIV.E.DE100 | Head circumference | |
HIV.E.DE101 | Mother HIV test conducted | |
HIV.E.DE102 | Mother HIV test ordered | |
HIV.E.DE103 | Mother HIV test date | |
HIV.E.DE104 | Maternal HIV test result | |
HIV.E.DE105 | HIV-positive | |
HIV.E.DE106 | HIV-negative | |
HIV.E.DE107 | HIV-inconclusive | |
HIV.E.DE108 | Infant or child exposure to HIV | |
HIV.E.DE109 | Not exposed | |
HIV.E.DE110 | HIV-exposed | |
HIV.E.DE111 | Unknown HIV exposure | |
HIV.E.DE112 | HIV-exposed infant or child | |
HIV.E.DE113 | Key population member | |
HIV.E.DE114 | Key population member type | |
HIV.E.DE115 | Sex worker | |
HIV.E.DE116 | People who inject drugs | |
HIV.E.DE117 | Trans and gender-diverse people | |
HIV.E.DE118 | People living in prisons and other closed setting | |
HIV.E.DE119 | Postpartum family planning counselling conducted | |
HIV.E.DE120 | Age of infant on HIV test date | |
HIV.E.DE121 | ARV adherence counselling | |
HIV.E.DE122 | Infant feeding counselling provided | |
HIV.E.DE123 | Date infant feeding counselling provided | |
HIV.E.DE124 | Malaria prevention counselling conducted | |
HIV.E.DE125 | Insecticide treated bednet (ITN) provided or referred | |
HIV.E.DE126 | Maternal syphilis treatment | |
HIV.E.DE127 | Infant feeding practice | |
HIV.E.DE128 | Exclusively breastfeeding | |
HIV.E.DE129 | Replacement feeding | |
HIV.E.DE130 | Mixed feeding | |
HIV.E.DE131 | Infant feeding practice recorded date | |
HIV.E.DE132 | Stopped breastfeeding | |
HIV.E.DE133 | Date stopped breastfeeding | |
HIV.E.DE134 | Taking iron and folic acid (IFA) tablets | |
HIV.E.DE135 | Amount of iron prescribed | |
HIV.E.DE136 | Type of iron supplement dosage provided | |
HIV.E.DE137 | Daily | |
HIV.E.DE138 | Weekly | |
HIV.E.DE139 | Amount of daily dose of folic acid prescribed | |
HIV.E.DE140 | Date infant ARV prophylaxis dispensed (or started) | |
HIV.E.DE141 | Maternal HIV status | |
HIV.E.DE142 | HIV-positive | |
HIV.E.DE143 | HIV-negative | |
HIV.E.DE144 | Unknown | |
HIV.E.DE145 | Maternal HIV status at first ANC visit | |
HIV.E.DE146 | HIV-positive | |
HIV.E.DE147 | HIV-negative | |
HIV.E.DE148 | Unknown | |
HIV.E.DE149 | Maternal syphilis test result | |
HIV.E.DE150 | Positive | |
HIV.E.DE151 | Negative | |
HIV.E.DE152 | Inconclusive | |
HIV.E.DE153 | Hypertension | |
HIV.E.DE154 | Pre-eclampsia | |
HIV.E.DE155 | Signs of substantial risk of HIV infection | |
HIV.E.DE156 | No condom use during sex with more than one partner in the past 6 months | |
HIV.E.DE157 | STI in the past 6 months | |
HIV.E.DE158 | A sexual partner in the past 6 months had one or more HIV risk factors | |
HIV.E.DE159 | PrEP requested by client | |
HIV.E.DE160 | Serodiscordant partner | |
HIV.E.DE161 | Date woman received counselling for CPT | |
HIV.E.DE162 | Date woman received counselling for TPT | |
HIV.E.DE163 | Infant's co-trimoxazole prophylaxis start date | |
HIV.E.DE164 | Infant's age when co-trimoxazole prophylaxis was started | |
HIV.E.DE165 | Presumptive clinical diagnosis of severe HIV infection in infants | |
HIV.E.DE166 | Infant ARV prophylaxis | |
HIV.E.DE167 | Infant ARV prophylaxis start date | |
HIV.E.DE168 | HIV test type | |
HIV.E.DE169 | Rapid diagnostic test for HIV | |
HIV.E.DE170 | Enzyme immunoassay for HIV | |
HIV.E.DE171 | Nucleic acid test for HIV | |
HIV.E.DE172 | Dual HIV/syphilis rapid diagnostic test | |
HIV.E.DE173 | Maternal and child health service visit | |
HIV.E.DE174 | 12-month visit | |
HIV.E.DE175 | 24-month visit | |
HIV.E.DE176 | First visit after the end of breastfeeding | |
HIV.E.DE177 | Weeks postpartum | |
HIV.E.DE178 | Birth cohort | |
HIV.E.DE179 | Registered in birth cohort | |
HIV.E.DE180 | EID sample number | |
HIV.E.DE181 | EID sample 1 | |
HIV.E.DE182 | EID sample 2 | |
HIV.E.DE183 | EID test number | |
HIV.E.DE184 | EID test number 1 | |
HIV.E.DE185 | EID test number 2 | |
HIV.E.DE186 | EID test number 1 test result | |
HIV.E.DE187 | Positive | |
HIV.E.DE188 | Negative | |
HIV.E.DE189 | Indeterminate | |
HIV.E.DE190 | EID test number 2 test result | |
HIV.E.DE191 | Positive | |
HIV.E.DE192 | Negative | |
HIV.E.DE193 | Indeterminate | |
HIV.E.DE194 | Assay number in testing strategy | |
HIV.E.DE195 | Assay 0 | |
HIV.E.DE196 | Assay 1 | |
HIV.E.DE197 | Assay 2 | |
HIV.E.DE198 | Assay 3 | |
HIV.E.DE199 | Assay 1 repeated | |
HIV.E.DE200 | Test result of HIV assay 1 | |
HIV.E.DE201 | Reactive | |
HIV.E.DE202 | Non-reactive | |
HIV.E.DE203 | Invalid | |
HIV.E.DE204 | Test result of HIV assay 2 | |
HIV.E.DE205 | Reactive | |
HIV.E.DE206 | Non-reactive | |
HIV.E.DE207 | Invalid | |
HIV.E.DE208 | Test result of HIV assay 3 | |
HIV.E.DE209 | Reactive | |
HIV.E.DE210 | Non-reactive | |
HIV.E.DE211 | Invalid | |
HIV.E.DE212 | Test result of HIV assay 1 repeated | |
HIV.E.DE213 | Reactive | |
HIV.E.DE214 | Non-reactive | |
HIV.E.DE215 | Invalid | |
HIV.E.DE216 | Test result of syphilis assay 1 | |
HIV.E.DE217 | Reactive | |
HIV.E.DE218 | Non-reactive | |
HIV.E.DE219 | Invalid | |
HIV.E.DE220 | Test result of syphilis assay 1 repeated | |
HIV.E.DE221 | Reactive | |
HIV.E.DE222 | Non-reactive | |
HIV.E.DE223 | Invalid | |
HIV.E.DE224 | HIV test date | |
HIV.E.DE225 | Infant HIV status | |
HIV.E.DE226 | HIV-positive | |
HIV.E.DE227 | HIV-negative | |
HIV.E.DE228 | Unknown | |
HIV.E.DE229 | Infant ART start date | |
HIV.E.DE230 | Final diagnosis of HIV-exposed infant | |
HIV.E.DE231 | HIV-positive | |
HIV.E.DE232 | HIV-negative and no longer breastfeeding | |
HIV.E.DE233 | HIV status unknown | |
HIV.E.DE234 | HIV-exposed infant reason for unknown final status | |
HIV.E.DE235 | Lost to follow-up | |
HIV.E.DE236 | Transferred out | |
HIV.E.DE237 | Death (documented) | |
HIV.E.DE238 | Refused (stopped) treatment | |
HIV.E.DE239 | Date of death of infant | |
HIV.E.DE240 | Cause of death of infant | |
HIV.E.DE241 | Infant died within 24 hours of childbirth | |
HIV.E.DE242 | Action(s) needed during infant follow-up visit | |
HIV.E.DE243 | Timing of additional infant HIV test | |
HIV.E.DE244 | Date of sample collection of additional infant HIV test | |
HIV.E.DE245 | Haemoglobin (Hb) result | |
HIV.E.DE246 | Blood group and Rh factor | |
HIV.E.DE247 | A+ | |
HIV.E.DE248 | A- | |
HIV.E.DE249 | B+ | |
HIV.E.DE250 | B- | |
HIV.E.DE251 | O+ | |
HIV.E.DE252 | O- | |
HIV.E.DE253 | AB+ | |
HIV.E.DE254 | AB- | |
HIV.E.DE255 | Asymptomatic bacteriuria (ASB) test result | |
HIV.E.DE256 | Positive | |
HIV.E.DE257 | Negative | |
HIV.E.DE258 | Unknown | |
HIV.E.DE259 | Urine protein test result | |
HIV.E.DE260 | 0 | |
HIV.E.DE261 | + | |
HIV.E.DE262 | ++ | |
HIV.E.DE263 | +++ | |
HIV.E.DE264 | Type of hypertensive disorder | |
HIV.E.DE265 | Chronic hypertension | |
HIV.E.DE266 | Essential | |
HIV.E.DE267 | Secondary | |
HIV.E.DE268 | White-coat hypertension | |
HIV.E.DE269 | Masked hypertension | |
HIV.E.DE270 | Gestational hypertension | |
HIV.E.DE271 | Transient gestational hypertension | |
HIV.E.DE272 | Pre-eclampsia | |
HIV.E.DE273 | Superimposed on chronic hypertension | |
HIV.G.DE1 | CD4 count | |
HIV.G.DE2 | CD4 cell percentage | |
HIV.G.DE3 | Baseline CD4 count | |
HIV.G.DE4 | Date of baseline CD4 count sample collection | |
HIV.G.DE5 | Late ART initiation | |
HIV.G.DE6 | Date of CD4 sample collection | |
HIV.G.DE7 | Viral load test conducted | |
HIV.G.DE8 | Date of viral load sample collection | |
HIV.G.DE9 | Date of first viral load sample collection | |
HIV.G.DE10 | Date viral load sample sent | |
HIV.G.DE11 | First viral load test result | |
HIV.G.DE12 | Viral load test result | |
HIV.G.DE13 | HIV viral load specimen type | |
HIV.G.DE14 | Liquid plasma specimen for viral load testing | |
HIV.G.DE15 | Dried blood spot specimen | |
HIV.G.DE16 | Dried plasma spot from a plasma separation card | |
HIV.G.DE17 | HBsAg test date | |
HIV.G.DE18 | HBsAg test result | |
HIV.G.DE19 | Positive | |
HIV.G.DE20 | Negative | |
HIV.G.DE21 | Indeterminate | |
HIV.G.DE22 | Reason Hepatitis B test not conducted | |
HIV.G.DE23 | Test delayed to next contact or referred | |
HIV.G.DE24 | Stock-out or expired | |
HIV.G.DE25 | Machine or technician not available or machine not functioning | |
HIV.G.DE26 | Client declined / refused test | |
HIV.G.DE27 | Other | |
HIV.G.DE28 | Other (specify) | |
HIV.G.DE29 | Hepatitis B diagnosis | |
HIV.G.DE30 | Hepatitis B positive | |
HIV.G.DE31 | Hepatitis B negative | |
HIV.G.DE32 | Hepatitis C screening date | |
HIV.G.DE33 | Hepatitis C test ordered | |
HIV.G.DE34 | Hepatitis C test conducted | |
HIV.G.DE35 | Reason Hepatitis C test not done | |
HIV.G.DE36 | Test delayed to next contact or referred | |
HIV.G.DE37 | Stock-out or expired | |
HIV.G.DE38 | Machine or technician not available or machine not functioning | |
HIV.G.DE39 | Client declined / refused test | |
HIV.G.DE40 | Other | |
HIV.G.DE41 | Other (specify) | |
HIV.G.DE42 | HCV test date | |
HIV.G.DE43 | HCV test result | |
HIV.G.DE44 | Positive | |
HIV.G.DE45 | Negative | |
HIV.G.DE46 | Indeterminate | |
HIV.G.DE47 | HCV viral load test date | |
HIV.G.DE48 | HCV viral load test result | |
HIV.G.DE49 | Detected | |
HIV.G.DE50 | Not detected | |
HIV.G.DE51 | Hepatitis C diagnosis | |
HIV.G.DE52 | Hepatitis C positive | |
HIV.G.DE53 | Hepatitis C negative | |
HIV.G.DE54 | Syphilis test required | |
HIV.G.DE55 | Syphilis test type | |
HIV.G.DE56 | Treponemal | |
HIV.G.DE57 | Non-treponemal | |
HIV.G.DE58 | POC Test | |
HIV.G.DE59 | NAAT | |
HIV.G.DE60 | Other | |
HIV.G.DE61 | Other syphilis test type (specify) | |
HIV.G.DE62 | Reason syphilis test not done | |
HIV.G.DE63 | Test delayed to next contact or referred | |
HIV.G.DE64 | Stock-out or expired | |
HIV.G.DE65 | Machine or technician not available or machine not functioning | |
HIV.G.DE66 | Client declined / refused test | |
HIV.G.DE67 | Other | |
HIV.G.DE68 | Other (specify) | |
HIV.G.DE69 | Syphilis test date | |
HIV.G.DE70 | Syphilis test result | |
HIV.G.DE71 | Positive | |
HIV.G.DE72 | Negative | |
HIV.G.DE73 | Inconclusive | |
HIV.G.DE74 | Syphilis diagnosis | |
HIV.G.DE75 | Syphilis positive | |
HIV.G.DE76 | Syphilis negative | |
HIV.G.DE77 | Other tests conducted | |
HIV.G.DE78 | Other test(s) name | |
HIV.G.DE79 | Other test(s) date | |
HIV.G.DE80 | Other test(s) result(s) | |
HIV.H.DE1 | Reason for follow-up | |
HIV.H.DE2 | Missed care visit | |
HIV.H.DE3 | Missed medication pickup | |
HIV.H.DE4 | Did not initiate ART | |
HIV.H.DE5 | Incomplete visit | |
HIV.H.DE6 | Inconclusive HIV status | |
HIV.H.DE7 | Test results received | |
HIV.H.DE8 | Other follow-up reason | |
HIV.H.DE9 | Other follow-up reason (specify) | |
HIV.H.DE10 | Client contact attempted | |
HIV.H.DE11 | Date of contact attempt | |
HIV.H.DE12 | Contact attempted by | |
HIV.H.DE13 | Contact method | |
HIV.H.DE14 | Home visit | |
HIV.H.DE15 | Text message | |
HIV.H.DE16 | Phone | |
HIV.H.DE17 | Source of information | |
HIV.H.DE18 | Client | |
HIV.H.DE19 | Informed by treatment provider | |
HIV.H.DE20 | Informed by family or partner | |
HIV.H.DE21 | Other source of information | |
HIV.H.DE22 | Other source of information (specify) | |
HIV.H.DE23 | Outcome from outreach attempt | |
HIV.H.DE24 | Returning to clinic | |
HIV.H.DE25 | Self-transferred out | |
HIV.H.DE26 | Hospitalized | |
HIV.H.DE27 | Refused to return | |
HIV.H.DE28 | Not located | |
HIV.H.DE29 | Died (reported) | |
HIV.H.DE30 | Moved from catchment area | |
HIV.H.DE31 | Date client moved from catchment area | |
HIV.H.DE32 | New catchment area | |
HIV.H.DE33 | Partner or contact of index case | |
HIV.H.DE34 | HIV status of partner or contact | |
HIV.H.DE35 | Already knew positive | |
HIV.H.DE36 | Newly diagnosed | |
HIV.H.DE37 | Negative | |
HIV.H.DE38 | Date of death | |
HIV.H.DE39 | Cause of death | |
HIV.H.DE40 | Place of death | |
HIV.H.DE41 | HIV treatment outcome | |
HIV.H.DE42 | Lost to follow-up | |
HIV.H.DE43 | Transferred out | |
HIV.H.DE44 | Death (documented) | |
HIV.H.DE45 | Refused (stopped) treatment | |
HIV.H.DE46 | Date patient lost to follow-up | |
HIV.H.DE47 | On ART | |
HIV.H.DE48 | Date HIV treatment outcome changed | |
HIV.H.DE49 | Transfer confirmed | |
HIV.H.DE50 | Transfer to facility | |
HIV.H.DE51 | Date of transfer out | |
HIV.H.DE52 | Adherence assessment | |
HIV.H.DE53 | Reason(s) for adherence problem | |
HIV.H.DE54 | Forgot | |
HIV.H.DE55 | Toxicity/side effects | |
HIV.H.DE56 | Busy | |
HIV.H.DE57 | Change of routine | |
HIV.H.DE58 | Travel cost | |
HIV.H.DE59 | Distance to clinic | |
HIV.H.DE60 | Client lost/ran out of pills | |
HIV.H.DE61 | Stock-out | |
HIV.H.DE62 | Too ill | |
HIV.H.DE63 | Pill burden | |
HIV.H.DE64 | Felt well | |
HIV.H.DE65 | Depression | |
HIV.H.DE66 | Alcohol use | |
HIV.H.DE67 | Substance use | |
HIV.H.DE68 | Stigma/disclosure concerns | |
HIV.H.DE69 | Lack of food | |
HIV.H.DE70 | Poor palatability | |
HIV.H.DE71 | Other | |
HIV.H.DE72 | Other (specify) | |
HIV.H.DE73 | Date ART stopped | |
HIV.H.DE74 | Reason ART stopped | |
HIV.H.DE75 | Toxicity/side effects | |
HIV.H.DE76 | Severe illness, hospitalization | |
HIV.H.DE77 | Drugs out of stock | |
HIV.H.DE78 | Client lacks finances | |
HIV.H.DE79 | Excluded HIV infection in infant | |
HIV.H.DE80 | Other reason for stopping ART | |
HIV.H.DE81 | Other reason for stopping ART (specify) | |
HIV.I.DE1 | Emergency referral | |
HIV.I.DE2 | Reason for referral | |
HIV.I.DE3 | Hospital | |
HIV.I.DE4 | Referral for screening including diagnostics and lab testing | |
HIV.I.DE5 | TB referral | |
HIV.I.DE6 | Antenatal care referral | |
HIV.I.DE7 | Referral for other general services | |
HIV.I.DE8 | Referral for other general services (specify) | |
HIV.I.DE9 | Any treatment given before referral? | |
HIV.I.DE10 | Date of scheduled referral appointment | |
HIV.I.DE11 | Location of scheduled referral appointment | |
HIV.I.DE12 | Date referral was made | |
HIV.I.DE13 | Provider who made referral | |
HIV.I.DE14 | Provider's facility | |
HIV.I.DE15 | Provider's telephone number | |
HIV.I.DE16 | Referral notes | |
HIV.I.DE17 | Client history summary | |
HIV.PRV.DE1 | At elevated risk for HIV acquisition | |
HIV.PRV.DE2 | HIV prevention intervention | |
HIV.PRV.DE3 | PrEP service | |
HIV.PRV.DE4 | OAMT | |
HIV.PRV.DE5 | NSP | |
HIV.PRV.DE6 | STI services | |
HIV.PRV.DE7 | VMMC | |
HIV.PRV.DE8 | Other | |
HIV.PRV.DE9 | Other (specify) | |
HIV.PRV.DE10 | Date accessed HIV prevention intervention | |
HIV.PRV.DE11 | HIV status of contact | |
HIV.PRV.DE12 | HIV-positive | |
HIV.PRV.DE13 | HIV-negative | |
HIV.PRV.DE14 | Unknown | |
HIV.PRV.DE15 | Date injecting equipment provided | |
HIV.PRV.DE16 | Number of needles-syringes provided | |
HIV.PRV.DE17 | Date OAMT initiated | |
HIV.PRV.DE18 | Date OAMT dose received | |
HIV.PRV.DE19 | Date OAMT take-away dose(s) dispensed | |
HIV.PRV.DE20 | Currently on OAMT | |
HIV.PRV.DE21 | Retained on OAMT | |
HIV.PRV.DE22 | Client being inducted on OAMT | |
HIV.PRV.DE23 | Client on reducing doses of OAMT | |
HIV.PRV.DE24 | Date first maintenance dose received | |
HIV.PRV.DE25 | Date of loss to follow-up or OAMT stopped | |
HIV.PRV.DE26 | Date medications dispensed | |
HIV.PRV.DE27 | Date medications prescribed | |
HIV.PRV.DE28 | Number of days prescribed | |
HIV.Config.DE1 | Population prevalence of TB | |
HIV.Config.DE2 | Population prevalence of soil-transmitted helminth infection | |
HIV.Config.DE3 | Population incidence of HIV in the absence of PrEP | |
HIV.Config.DE4 | Population prevalence of HIV | |
HIV.Config.DE5 | Prevalence of pretreatment NNRTI drug resistance | |
HIV.Config.DE6 | Malaria-endemic setting | |
HIV.Config.DE7 | Population prevalence of syphilis | |
HIV.Config.DE8 | Population prevalence of hepatitis B | |
HIV.Config.DE9 | Population prevalence of hepatitis C | |
HIV.Config.DE10 | Prevalence of HIV in the catchment area | |
HIV.Config.DE11 | Ultrasound available at the health facility | |
HIV.Config.DE12 | HIV burden of the setting | |
HIV.Config.DE13 | High HIV burden setting | |
HIV.Config.DE14 | Low HIV burden setting | |
HIV.Config.DE15 | HPV DNA testing operational at the health facility | |
HIV.Config.DE16 | Routine viral load testing is available | |
HIV.Config.DE17 | Health facility ID | |
HIV.Config.DE18 | TB treating facility ID | |
HIV.Config.DE19 | Other priority populations | |
HIV.Config.DE20 | Reporting period end date | |
HIV.Config.DE21 | Reporting period start date | |
HIV.Config.DE22 | Reporting date | |